



## CLINICAL PRACTICE GUIDELINES

### V Spanish Consensus Conference on *Helicobacter pylori* infection treatment<sup>☆,☆☆</sup>



Javier P. Gisbert<sup>a,\*</sup>, Javier Alcedo<sup>b</sup>, Javier Amador<sup>c</sup>, Luis Bujanda<sup>d</sup>, Xavier Calvet<sup>e</sup>, Manuel Castro-Fernández<sup>f</sup>, Luis Fernández-Salazar<sup>g</sup>, Emili Gené<sup>h</sup>, Ángel Lanas<sup>i</sup>, Alfredo Lucendo<sup>j</sup>, Javier Molina-Infante<sup>k</sup>, Olga P. Nyssen<sup>a</sup>, A. Pérez-Aisa<sup>l</sup>, Ignasi Puig<sup>m</sup>

<sup>a</sup> Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

<sup>b</sup> Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain

<sup>c</sup> Medicina de Familia, Centro de Salud Los Ángeles, Dirección Asistencial Centro, SERMAS, Madrid, Spain

<sup>d</sup> Servicio de Aparato Digestivo, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco UPV/EHU, CIBEREHD, San Sebastián, Spain

<sup>e</sup> Servicio de Aparato Digestivo, Hospital Parc Taulí, Universitat Autònoma de Barcelona, CIBEREHD, Sabadell, Barcelona, Spain

<sup>f</sup> Servicio Aparato Digestivo, Hospital Universitario de Valme, CIBEREHD, Sevilla, Spain

<sup>g</sup> Servicio de Aparato Digestivo, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud (SACYL). Universidad de Valladolid, Valladolid, Spain

<sup>h</sup> Servicio de Urgencias, Hospital Parc Taulí Sabadell, CIBEREHD, Universitat Internacional de Catalunya, Barcelona, Spain

<sup>i</sup> Servicio de Aparato Digestivo, Hospital Clínico Universitario de Zaragoza, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), CIBEREHD, Zaragoza, Spain

<sup>j</sup> Servicio de Aparato Digestivo, Hospital General de Tomelloso, CIBEREHD, Ciudad Real, Spain

<sup>k</sup> Servicio de Aparato Digestivo, Hospital Universitario de Cáceres, CIBEREHD, Cáceres, Spain

<sup>l</sup> Servicio de Aparato Digestivo, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain

<sup>m</sup> Servicio de Aparato Digestivo, Althaia Xarxa Assistencial Universitària de Manresa, Universitat de Vic-Universitat Central de Catalunya (UVicUCC), Manresa, Barcelona, Spain

#### KEYWORDS

Bismuth;  
Clarithromycin;  
*Helicobacter pylori*;

**Abstract** *Helicobacter pylori* infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on *H. pylori* infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing

\* Please cite this article as: Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, et al. V Conferencia Española de Consenso sobre el tratamiento de la infección por *Helicobacter pylori*. Gastroenterol Hepatol. 2022;45:392–417.

☆☆ This article is published simultaneously in [Gastroenterología y Hepatología – [<https://doi.org/10.1016/j.gastre.2021.07.001>]] and [Revista Española de Enfermedades Digestivas – [<https://doi.org/10.17235/reed.2021.8358/2021>]], with the consent of the authors and editors.

\* Corresponding author.

E-mail address: [javier.p.gisbert@gmail.com](mailto:javier.p.gisbert@gmail.com) (J.P. Gisbert).

Proton pump inhibitor;  
Levofloxacin;  
Metronidazole;  
Omeprazole;  
Tetracycline

the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of *H. pylori* infection in peptic ulcer disease were also reviewed.

© 2021 Elsevier España, S.L.U. All rights reserved.

## PALABRAS CLAVE

Bismuto;  
Claritromicina;  
*Helicobacter pylori*;  
Inhibidor de la bomba de protones;  
Levofloxacino;  
Metronidazol;  
Omeprazol;  
Tetraciclina

## V Conferencia Española de Consenso sobre el tratamiento de la infección por *Helicobacter pylori*

**Resumen** La infección por *Helicobacter pylori* es muy frecuente entre la población española y representa la causa fundamental de gastritis crónica, úlcera péptica y cáncer gástrico. Previamente se han llevado a cabo cuatro reuniones de Consenso sobre el manejo de la infección por *H. pylori* en España, la última de ellas en 2016. Los cambios en los esquemas de tratamiento y la creciente evidencia disponible al respecto han justificado la organización de esta V Conferencia Española de Consenso en mayo de 2021, centrada en el tratamiento de esta infección. Participaron 14 expertos sobre el tema, que realizaron una búsqueda sistemática de la evidencia científica y elaboraron una serie de recomendaciones que fueron sometidas a un proceso de interacción de votaciones anónimas seriadas mediante metodología Delphi. Para clasificar la evidencia científica y la fuerza de las recomendaciones, se utilizó el sistema GRADE. Este consenso establece, como punto de partida, un aumento de la exigencia en la eficacia de los tratamientos recomendados, que deben alcanzar, o preferiblemente superar, el 90% de curación al ser administrados empíricamente. De este modo, tanto en primera como en segunda línea se recomiendan tratamientos cuádruples con o sin bismuto, generalmente prescritos durante 14 días. Como tratamiento de primera línea se recomienda una pauta cuádruple concomitante sin bismuto (inhibidor de la bomba de protones, claritromicina, amoxicilina y metronidazol) o una combinación cuádruple con bismuto (inhibidor de la bomba de protones, bismuto, tetraciclina y metronidazol). En el presente consenso se revisan también con detalle otras alternativas de tratamiento de rescate.

© 2021 Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

(*H. pylori*) infection affects around 50% of the world population and plays a fundamental role in the development of various digestive diseases such as chronic gastritis, peptic ulcer and gastric cancer. Therefore, its proper diagnosis and effective treatment are crucial in clinical practice. In Spain, four consensus meetings on *H. pylori* infection have been organised to date: in 1999,<sup>1,2</sup> 2004,<sup>3,4</sup> 2012,<sup>5</sup> and the last in 2016.<sup>6</sup> The notable changes that have occurred in treatment regimens and the growing evidence available on the subject (especially in our setting) have justified the organisation of this V Spanish Consensus Conference in May 2021. Since there have been no significant advances in aspects related to indications for treatment or diagnostic techniques for the infection, this consensus conference will focus exclusively

on updating the recommendations on the treatment of *H. pylori* infection.

## Methodology

**Participants in the consensus:** Spanish researchers were invited to participate who had published at least five articles during the last five years on the treatment of *H. pylori* infection, identified by the search strategy "*Helicobacter pylori AND Spain*" in PubMed. In all, 14 experts, including gastroenterologists, primary care physicians, and experts in scientific methodology and evidence-based medicine, were invited and all of them accepted. A gastroenterologist (JPG) acted as coordinator. The recommendations on the eradi-

cation treatment of *H. pylori* of this consensus group are primarily directed and applied to the adult population.

**Bibliographic searches:** priority was given to identifying systematic reviews and other documents of critical synthesis of the scientific literature. The following electronic databases were consulted: TRIP Database, NHS National Library of Guidelines, National Guideline Clearinghouse, Cochrane Database of Systematic Reviews (The Cochrane Library), Database of Abstracts of Reviews of Effects (DARE) and MEDLINE (access through PubMed). In a second phase, a search of individual studies, randomised clinical trials and observational studies was carried out, as well as a review of the bibliographic references of the documents included.

**Classification of scientific evidence and strength of recommendations:** to classify the scientific evidence and the strength of the recommendations, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used (<http://www.gradeworkinggroup.org/>). The GRADE system is a structured and explicit classification that has been widely adopted internationally, which has the advantage of overcoming the limitations of previous systems and standardising the system for formulating recommendations.<sup>7,8</sup>

**Evaluation of the recommendations by the consensus group:** the recommendations were initially drawn up by the coordinator. Subsequently, they were subjected to a process of interaction via a series of votes, using Delphi methodology.<sup>9</sup> Two rounds of electronic voting were carried out.

For each recommendation, the participants rated their degree of agreement using a 6-point Likert scale (1: totally disagree; 2: strongly disagree; 3: somewhat disagree; 4: somewhat agree; 5: strongly agree; 6: totally agree). Any rating lower than 6 required the evaluators to make suggestions for improvement. After each vote, the coordinator reviewed the recommendations according to the comments and votes received, integrating the suggestions to maximise agreement. A recommendation was approved if more than 75% of the participants agreed (score 4–6 on the Likert scale).

**Ethical aspects:** the consensus was adjusted to the established ethical recommendations.<sup>10</sup> Participants made conflict of interest declarations before and after the Delphi voting process (see the section Conflicts of interest).

**Sponsorships, endorsements and funding:** the conference was scientifically sponsored by the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) [Biomedical Research Networking Centre for Liver and Digestive Diseases]. This consensus document has been endorsed by the Asociación Española de Gastroenterología [Spanish Association of Gastroenterology] and by the Sociedad Española de Patología Digestiva [Spanish Society of Digestive Pathology], which have adhered to and support the consensus recommendations. There has been no funding from the pharmaceutical industry.

## Recommendations

Each recommendation is accompanied by the result of the vote (percentage of agreement), the grade of recommenda-

tion (GR; strong or weak), the quality of the evidence (QE; high, moderate, low or very low) and the discussion of the corresponding evidence.

All the recommendations approved in this Spanish consensus on the treatment of *H. pylori* infection are included in Table 1. The drugs, duration and dose of each of the components of the recommended guidelines are detailed in Table 2. Finally, the algorithm for the initial and rescue treatment for the infection is shown in Fig. 1.

Since the advantage of guiding eradication therapy by studying the antimicrobial susceptibility of *H. pylori* compared to the empirical administration of treatment has not been sufficiently confirmed,<sup>11–14</sup> and as this study is not generally accessible,<sup>15,16</sup> the comments included in this consensus document have been based on the assumption that the individual susceptibility (of the particular patient) is unknown. Nevertheless, it seems reasonable to recommend routine susceptibility testing (culture or PCR), even before prescribing a first-line eradication therapy, in specialised centres interested in the management of *H. pylori* infection. In any case, the scope of application of this consensus is limited to Spanish territory and to other geographic areas that present a similar frequency of antibiotic resistance to the recommended drugs, especially clarithromycin, metronidazole and levofloxacin.

**Recommendation 1.** Currently, it is recommended that an eradication therapy be considered effective when it is capable of curing *H. pylori* infection in close to, or preferably more than, 90% of patients.

100% agreement; votes: totally agree (85.7%); strongly agree (14.3%). GR: strong. QE: very low.

The goal of treatment aimed at eliminating any microorganism should be to achieve 100% success, and *H. pylori* infection should not be an exception.<sup>17</sup> However, in all the initial European<sup>18–21</sup> and Spanish<sup>2,4,5</sup> consensus guidelines, it was established that a cure rate equal to or greater than 80% could be considered sufficient. Given that we currently have antibiotic therapies with cure rates close to or even higher than 90% for most bacterial infections, it is considered that this efficacy threshold – albeit arbitrary – should also be that required for a treatment, both first-line and rescue, to be considered effective against *H. pylori* infection (although it is true that in second-line and successive treatments this threshold may be more difficult to reach). These eradication figures ( $\geq 90\%$ ) refer to the intention-to-treat (ITT) analysis, that is, considering the worst scenario (penalised by the possible incorrect compliance with the treatment by the patient) and not only taking into account clinical trials but also, and fundamentally, clinical practice studies. To achieve this goal, all treatments must be optimised in terms of duration, dose and interval of administration of proton pump inhibitors (PPIs) and antibiotics<sup>22,23</sup> (Fig. 1).

**Recommendation 2.** As first-line treatment for *H. pylori* infection, a concomitant non-bismuth quadruple regimen (PPI, clarithromycin, amoxicillin and metronidazole) or a quadruple combination with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended.

100% agreement; votes: totally agree (100%). GR: strong. QE: moderate.

The choice of first-line treatment for *H. pylori* infection will depend primarily on the rate of resistance of this bacterium to the prescribed antibiotics.<sup>24</sup> The classic

**Table 1** Recommendations for the treatment of *H. pylori* infection.

<b>Recommendation 1.</b> Currently, it is recommended that an eradication therapy be considered effective when it is capable of curing <i>H. pylori</i> infection in close to, or preferably more than, 90% of patients.
<b>Recommendation 2.</b> As first-line treatment for <i>H. pylori</i> infection, a concomitant non-bismuth quadruple regimen (PPI, clarithromycin, amoxicillin and metronidazole) or a quadruple combination with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended.
<b>Recommendation 3.</b> It is recommended that the duration of concomitant non-bismuth quadruple therapy (PPI, clarithromycin, amoxicillin and metronidazole) be 14 days.
<b>Recommendation 4.</b> It is recommended that the duration of quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) be at least 10 days.
<b>Recommendation 5.</b> In patients allergic to penicillin, a quadruple regimen with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended as first-line treatment.
<b>Recommendation 6.</b> It is not recommended to combine probiotics with eradication therapy.
<b>Recommendation 7.</b> After the failure of a first treatment that includes clarithromycin (triple or quadruple), a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended. Another option is a quadruple regimen with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth).
<b>Recommendation 8.</b> After the failure of a first treatment with a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple regimen with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth) is recommended.
<b>Recommendation 9.</b> rescue treatment in patients allergic to penicillin:
a) After the failure of a first triple treatment (PPI, clarithromycin and metronidazole), it is suggested to use a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole).
b) After the failure of a first quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple therapy with PPI, levofloxacin, clarithromycin and bismuth is suggested.
<b>Recommendation 10.</b> After the failure of a first treatment with clarithromycin and a second treatment with levofloxacin, a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended.
<b>Recommendation 11.</b> After the failure of a first treatment with clarithromycin and a second-line quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple therapy with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth) is recommended.
<b>Recommendation 12.</b> After the failure of a first quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) and a second-line treatment with levofloxacin, a concomitant quadruple therapy (PPI, amoxicillin, clarithromycin and metronidazole) is suggested.
<b>Recommendation 13.</b> After the failure of a third treatment, it is suggested to carefully reevaluate the need to eradicate the infection and, where appropriate, to indicate a fourth-line treatment with rifabutin.
<b>Recommendation 14.</b> In patients with uncomplicated duodenal ulcer who do not require non-steroidal anti-inflammatory drugs/aspirin, it is not recommended to continue antisecretory therapy after completing the <i>H. pylori</i> eradication therapy.
<b>Recommendation 15.</b> In patients with gastric ulcers who do not require NSAIDs/aspirin, it is recommended to maintain the antisecretory therapy for 4–8 weeks after the end of the <i>H. pylori</i> eradication therapy.
<b>Recommendation 16.</b> In patients with gastrointestinal bleeding from peptic ulcer, the eradication of <i>H. pylori</i> eliminates practically all relapses. Therefore, once eradication is confirmed and if the patient is not taking non-steroidal anti-inflammatory drugs/aspirin, it is recommended not to administer maintenance treatment with antisecretory drugs.

triple therapy (PPI, clarithromycin and amoxicillin) is not recommended when the resistance rate to clarithromycin is greater than 15%,<sup>25</sup> since the eradication figures are unacceptably low above this threshold.<sup>22</sup> Other factors that influence the efficacy of eradication therapy are the patient's adherence and their previous history of antibiotic use, which could determine the choice of the first therapeutic option.<sup>22,26,27</sup> The available evidence regarding potential first-line treatment guidelines is reviewed below.

### Triple therapy (PPI, clarithromycin and amoxicillin)

The mean efficacy of triple therapy in Spain was 80% and 70% in two systematic reviews published in 2011 and 2013.<sup>28,29</sup> The efficacy of such treatment in the studies published later in Spain has usually been less than 75%.<sup>30–34</sup> The European Registry on *H. pylori* Management (Hp-EuReg) provides us

with information of great interest in this regard. More than 300 researchers from 30 countries participate in this registry, which evaluates how *H. pylori* infection is managed by European gastroenterologists.<sup>35</sup> When analysing the Spanish data from this registry, which included approximately 3000 patients from 2013 to 2020, it was found that the eradication rate achieved with triple treatment with clarithromycin was only 80%, in the "modified" ITT analysis<sup>36</sup> (this analysis aims to obtain a result as close as possible to that of clinical practice, including all patients who complete follow-up and in whom a confirmatory test of eradication success is performed, regardless of treatment compliance; henceforth, when the Hp-EuReg results are mentioned, we will always be referring to this analysis). Despite these poor results, this treatment continues to be used with some frequency in Spain (and in Europe<sup>37</sup>), especially in the primary care context.<sup>38</sup> The use of vonoprazan (a competitive H<sup>+</sup>/K<sup>+</sup> ATPase pump inhibitor), instead of a PPI, is associated with


**Table 2** Drugs, dose and duration of recommended *H. pylori* eradication treatments.

Treatment	Drug	Dosage	Duration (days)
Non-bismuth quadruple therapy (concomitant)	PPI Amoxicillin Clarithromycin Metronidazole	Standard dose*/12 h 1 g/12 h 500 mg/12 h 500 mg/12 h	14
Quadruple therapy with bismuth (Pylera®)	PPI Pylera®	Standard dose/12 h 3 capsules/6 h**	10
Quadruple therapy with levofloxacin and bismuth	PPI Amoxicillin Levofloxacin Bismuth subcitrate	Standard dose*/12 h 1 g/12 h 500 mg/24 h 240 mg/12 h	14
Rifabutin therapy	PPI Amoxicillin Rifabutin ± Bismuth subcitrate	Standard dose/12 h 1 g/12 h 150 mg/12 h 240 mg/12 h	10–12

PPI: proton pump inhibitor.

\* The benefit of administering a latest generation PPI (rabeprazole or esomeprazole) and the use of double PPI doses is not clearly established, unlike what occurs with standard triple treatment. However, it is possible that these optimisations also add eradicating benefits to these therapeutic regimens.<sup>68</sup>

\*\* Although this is the dose included in the SmPC, a recent study based on data from the European Registry on *Helicobacter pylori* management (Hp-EuReg) suggests that the dose of 4 capsules/8 h could have a similar effectiveness and tolerance.<sup>264</sup>



**Figure 1** Algorithm for initial and rescue treatment of *H. pylori* infection.  
h: hours; PPI: proton pump inhibitor.

a marked increase in the efficacy of triple therapy (and even dual therapy with clarithromycin alone),<sup>39–44</sup> but studies are still scarce and there has been no experience with this drug in our setting, where it is not yet marketed.

The mean rate of resistance to clarithromycin in Spain was 14% in 2009<sup>45</sup> and 17–18% in more updated reviews.<sup>27,29</sup> A recent Spanish study has shown a clarithromycin resistance rate of 34% in children,<sup>46</sup> while in adults the figures published in recent studies have been approximately 20%.<sup>47–50</sup> Cumulatively, all this evidence points to continuing with the recommendation not to prescribe triple therapy as first-line treatment in Spain, especially when there are currently therapeutic alternatives capable of obtaining significantly better cure rates.<sup>51</sup> These include quadruple therapies with or without bismuth, which will be reviewed below.

### **Non-bismuth quadruple therapies (PPI, amoxicillin, clarithromycin and metronidazole)**

The efficacy of non-bismuth quadruple therapies will depend fundamentally on the rate of dual resistance (at the same time) to clarithromycin and metronidazole.<sup>22</sup> So-called "concomitant" therapy is the most effective non-bismuth quadruple therapy in high-resistance situations. It has been estimated that sequential, hybrid, and concomitant therapy will achieve cure rates >90% when this double resistance rate is below 5%, 9%, and 15%, respectively. In our setting, the dual resistance rate is still below 15%. Various studies carried out with concomitant therapy in many different countries have shown an efficacy close to or greater than 90% in the ITT analysis.<sup>52–54</sup> A recent systematic review and meta-analysis that included 107 studies (55 of them randomised) and almost 30,000 patients, calculated a mean efficacy of concomitant therapy of approximately 90% (with good results even in the presence of resistance to clarithromycin or metronidazole), with results superior to standard triple treatment and sequential treatment.<sup>55</sup> However, in certain regions of Europe and Asia, with much higher rates of resistance to clarithromycin and metronidazole, the efficacy of concomitant therapy has been suboptimal.<sup>56–59</sup> The results obtained with this concomitant quadruple therapy in various studies carried out in Spain are summarised in Table 3, with a mean eradication efficacy of approximately 90%.<sup>30,32,33,60–67</sup> When considering the Spanish studies that prescribe this treatment for 14 days, the eradication rates range between 89% and 92%, which is significantly higher than those obtained by classic triple therapy optimised and prolonged up to two weeks (81%).<sup>63</sup> These favourable results have been described not only when the prescription has been made by gastroenterologists but also in the primary care context.<sup>67</sup> Finally, the Hp-EuReg data have confirmed the excellent results of concomitant therapy, both in Europe in general<sup>68,69</sup> and in Spain in particular,<sup>36</sup> with eradication rates (by ITT) higher than 90% in both cases (if the treatment was prescribed for 14 days, which, as is specified below, is considered the appropriate duration).

Regarding sequential therapy (PPI together with amoxicillin during the first 5–7 days, followed by PPI together with clarithromycin and metronidazole during the last 5–7 days), various studies and meta-analyses have shown that it is not superior to 14-day triple therapy.<sup>70–74</sup> Meanwhile,

concomitant therapy is significantly superior to sequential therapy when both are prescribed for a similar duration.<sup>54</sup> Furthermore, suboptimal results have been published with sequential therapy in our setting.<sup>62,75,76</sup> Therefore, the use of sequential therapy is currently discouraged.

In summary, as a first-line treatment for *H. pylori* infection in Spain, a concomitant a non-bismuth quadruple regimen is recommended as one of the options. The duration and dose of its components (i.e., PPI, clarithromycin, amoxicillin, and metronidazole) are summarised in Table 2. For more details about the duration of concomitant therapy, see recommendation 3.

### **Quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole)**

Quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) represents a valid alternative to non-bismuth quadruple therapy, since it consists of drugs, such as bismuth and tetracycline, against which *H. pylori* is never or only exceptionally resistant.<sup>77</sup> Meanwhile, resistance to metronidazole can be partially compensated by prolonged use of this antibiotic, at short intervals and with high doses.<sup>77</sup>

Three meta-analyses carried out in the last decade have coincided in emphasising that quadruple therapy with bismuth (mean efficacy: 81%, 78%, 77%) does not offer any advantage over triple therapy.<sup>78–80</sup> However, quadruple therapy with bismuth was prescribed for only 7 days in the studies on which these meta-analyses are based, and these were also published a decade or more ago, when clarithromycin resistance rates (which reduce the efficacy of triple therapy) were considerably lower. In fact, a multicentre clinical trial, carried out between 2013 and 2016, in a geographic area with high resistance to clarithromycin, concluded that quadruple therapy with bismuth administered for 10 days was superior to the classic 14-day triple therapy (efficacy of 90% vs. 84%).<sup>81</sup>

The experience in Spain and in other countries with conventional bismuth quadruple therapy has been limited by the lack of availability of tetracycline hydrochloride, and by the fact that doxycycline (which is marketed here) is associated with worse results.<sup>82</sup> The recent marketing of Pylera® (a capsule containing bismuth, tetracycline and metronidazole), has once again permitted the prescription of this therapeutic combination. A European multicentre trial initially demonstrated good results with Pylera® administered for 10 days, reaching an efficacy by ITT analysis (based on the result of a breath test) of 90%, significantly higher than that of triple therapy.<sup>83</sup> Subsequently, numerous studies have been published, which have been summarised in a recent meta-analysis, showing that treatment with first-line Pylera® (21 studies included) achieved an eradication efficacy (by ITT) of 90%.<sup>84</sup> These results were obtained regardless of the type and dose of PPI, and even in patients infected with strains of *H. pylori* resistant to clarithromycin or metronidazole.<sup>84</sup> In fact, the high efficacy of this first-line treatment regimen (close to or greater than 90%) has been demonstrated in two recent studies carried out in China and Thailand,<sup>85,86</sup> countries with a very high rate of resistance to clarithromycin (approximately 50%). The tolerance of this treatment is

**Table 3** Studies evaluating the efficacy of first-line concomitant non-bismuth quadruple therapy in Spain.

Author and year of publication	No. of patients	Duration (days)	PPI type and dose	Eradication
Molina-Infante <sup>60</sup> , 2012	209	10	PPI standard dose/12 h	86%
Molina-Infante <sup>61</sup> , 2013	170	14	Omeprazole 40 mg/12 h	92%
McNichol <sup>62</sup> , 2014	168	10	Omeprazole 20 mg/12 h	87%
Molina-Infante <sup>63</sup> , 2015	375	14	Esomeprazole 40 mg/12 h	90%
Cuadrado-Lavin <sup>30</sup> , 2015	120	10	Omeprazole 20 mg/12 h	90%
McNichol <sup>64</sup> , 2015	630	14	Esomeprazole 40 mg/12 h	91%
Cosme <sup>65</sup> , 2016	118	10	Omeprazole 20 mg/12 h	87%
Campillo <sup>32</sup> , 2016	371	10	PPI various doses/12 h	86%
Campillo <sup>32</sup> , 2016	108	10	Esomeprazole 40 mg/12 h	91%
Campillo <sup>33</sup> , 2016	298	10	PPI various doses/12 h	85%
McNichol <sup>66</sup> , 2018	70	10	PPI standard dose/12 h	96%
Olmedo <sup>67</sup> , 2020	112	14	Omeprazole 20 mg/12 h	89%

“Intention-to-treat” eradication rates.

PPI: proton pump inhibitor.

acceptable, although the incidence of adverse effects is relatively high (as is the case with all eradication therapies<sup>87</sup>). Most are mild, and only exceptionally do they oblige the suspension of treatment.<sup>36,84,88</sup>

The results obtained with Pylera® in various studies carried out in Spain are summarised in Table 4, showing a mean efficacy of approximately 90%.<sup>89–94</sup> The Hp-EuReg data have confirmed these excellent results, both in Europe in general<sup>88</sup> and in Spain in particular<sup>36</sup> (currently with more than 2500 patients treated with Pylera®), obtaining eradication rates above 90%. A very recent update of this registry, including in this case more than 5000 patients, has once again confirmed these findings (94% eradication by ITT, as first-line treatment).<sup>95</sup>

Finally, a very recent meta-analysis has summarised the clinical trials that compared bismuth versus concomitant quadruple therapy as first-line therapy (10 studies, although not all used the standard guidelines of these regimens) and has shown similar efficacy and safety with both therapies.<sup>96</sup> In particular, a Spanish prospective (although not randomised) study compared these two regimens (Pylera® for 10 days versus concomitant for 14 days) and has shown similar eradication rates (94% and 98%, respectively), with similar tolerance.<sup>92</sup> Another more recent Spanish study, also prospective (although not randomised), has again confirmed that both therapies (Pylera® and concomitant) are equivalent (eradication rates of 88% and 86%, respectively).<sup>94</sup>

A variant of quadruple therapy with bismuth consists of adding this drug to the classic triple therapy (that is, the combination of a PPI, clarithromycin, amoxicillin and bismuth), with which good results have been obtained in some studies.<sup>23</sup> However, experience with this treatment in our setting is very limited (just one study has been published in Spain<sup>97</sup>) and the results in other countries have not always been very encouraging.<sup>23</sup>

In summary, quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), and in particular using the Pylera® formulation, can now be considered a valid first-line alternative, together with concomitant therapy. The duration and dose of its components are summarised in Table 2. For more details about the duration of treatment, see recommendation 4.

**Recommendation 3.** It is recommended that the duration of concomitant non-bismuth quadruple therapy (PPI, clarithromycin, amoxicillin and metronidazole) be 14 days.

100% agreement; votes: totally agree (100%). GR: strong. QE: moderate.

Concomitant non-bismuth quadruple therapy, developed in the late 1990s, was initially designed to reduce the duration of eradication therapy.<sup>53</sup> In fact, initial studies in Germany and Japan suggested that a duration of 3–5 days could be sufficient to achieve acceptable cure rates.<sup>98,99</sup> However, more recently, several clinical trials that compared this therapy with different durations have shown higher cure rates with longer treatments: 3 days (81%) vs. 5 days (89%)<sup>100</sup>; 5 days (87%) vs. 7 days (90%)<sup>101</sup>; 5 days (89%) vs. 10 days (96%)<sup>102</sup>; 5 days (78%) vs. 14 days (86%)<sup>103</sup>; 10 days (80%) vs. 14 days (96%).<sup>104</sup> In a recent non-randomised Spanish study, a 14-day concomitant therapy (together with a high PPI dose) was superior to a 10-day treatment (with a standard PPI dose; 87% vs. 91%, p < 0.01).<sup>64</sup> Similarly, the first meta-analysis published on this therapy showed that the efficacy of concomitant therapy was dependent on its duration.<sup>52</sup> In the Hp-EuReg, concomitant therapy was administered to 4164 patients, confirming a higher eradication rate with the 14-day versus 10-day regimens (92% vs. 88%).<sup>68</sup> Finally, this same trend can be observed in the collective Spanish experience obtained in recent years, where 14-day treatments are the only ones that have consistently reached (or even exceeded) the 90% efficacy threshold (Table 3).

In summary, it is currently recommended that the duration of concomitant quadruple therapy be 14 days.

**Recommendation 4.** It is recommended that the duration of quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) be at least 10 days.

100% agreement; votes: totally agree (100%). GR: strong. QE: moderate.

It has been suggested that 10-day quadruple therapy with bismuth would be highly effective against strains sensitive to metronidazole, but it is possible that a 14-day is more effective than a 10-day therapy against microorganisms resistant to this antibiotic.<sup>85</sup> However, various studies have suggested

**Table 4** Studies evaluating the efficacy of first-line therapy with Pylera® in Spain.

Author and year of publication	No. of patients	Duration (days)	PPI type and dose	Eradication
Gómez Rodríguez <sup>89</sup> , 2017	41	10	Omeprazole 20 or 40 mg/12 h	98%
Agudo-Fernández <sup>90</sup> , 2018	107	10	PPI/12 h	78%
Pérez-Arellano <sup>91</sup> , * , 2018	100	10	Omeprazole 40 mg/12 h	91%
Macías-García <sup>92</sup> , 2019	54	10	Omeprazole 20 mg/12 h	94%
Castro-Fernández <sup>93</sup> , 2019	200	10	Omeprazole 20 or 40 mg or esomeprazole 40 mg/12 h	91%
Alcedo <sup>94</sup> , 2020	212	10	Omeprazole 20 mg/12 h	88%

“Intention-to-treat” eradication rates.

PPI: proton pump inhibitor.

\* Probiotics combined with treatment.

that a duration of 10 days might be sufficient, as reviewed below.

In a meta-analysis published in 2004 on different eradication therapies, it was observed that the efficacy of bismuth quadruple therapy administered for 1–3, 4, and 7 days was lower than with a duration of 10–14 days.<sup>105</sup> Likewise, it was found that a duration equal to or greater than 10 days achieved cure rates higher than 85%, even in regions with a high prevalence of resistance to metronidazole.<sup>105</sup> To date, there is only one study (including 417 patients) that directly compares 10-day and 14-day quadruple therapy with bismuth, and found no differences between the two regimens (92% vs. 93%).<sup>106</sup>

Meanwhile, in recent years excellent results have been obtained with bismuth quadruple therapy being presented in a single capsule (Pylera®), which is sold in packs/bottles that imply its prescription for 10 days. Thus, a recent meta-analysis, that included 30 studies and more than 6000 patients treated with Pylera® for 10 days, confirmed an efficacy (by ITT) of 90% as first-line treatment.<sup>84</sup> In eight studies, the proportion of patients with resistance to clarithromycin or metronidazole was estimated, and Pylera® was highly effective despite the presence of such resistance.<sup>84</sup>

Finally, the Hp-EuReg has recently analysed the effectiveness of Pylera® (10 days) in clinical practice in various European countries (mainly Spain, Italy and Portugal), where 2100 patients were evaluated.<sup>88</sup> Its efficacy (by ITT) was 95% as first-line, 89% as second-line, and 92% as third- to sixth-line rescue treatment.<sup>88</sup> Although a culture was performed only to evaluate antibiotic resistance in 48 cases, Pylera® was also effective (>90%) in those patients with *H. pylori* strains resistant to clarithromycin or metronidazole, or to both.<sup>88</sup> A very recent update of this European registry included more than 5000 patients treated with this 10-day bismuth quadruple therapy in a single capsule and confirmed the excellent eradication rates (by ITT): 94% as first-line treatment, 90% as second-line, and 86% in subsequent treatment lines.<sup>95</sup>

Unfortunately, there are no studies that directly compare the traditional bismuth quadruple therapy (with its components administered separately) and Pylera® (in a single capsule), nor between different durations (10 vs. 14 days) of the latter presentation. Therefore, comparative studies evaluating the efficacy, safety and cost of different regimens are necessary to clarify the ideal duration of bismuth quadruple therapy, especially depending on the pattern of resistance to metronidazole. In the meantime, it seems prudent to recommend that the duration of this treatment be at least 10 days.

**Recommendation 5.** In patients allergic to penicillin, a quadruple regimen with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended as first-line treatment.

100% agreement; votes: totally agree (100%). GR: strong. QE: moderate.

Amoxicillin is one of the most effective antimicrobial agents against *H. pylori* and therefore many of the eradication therapies include this antibiotic. Until now, experience with eradication therapy in patients allergic to penicillin has been limited, although in clinical practice this circumstance is relatively common. However, it must be taken into account that only a minority of patients who report a (theoretical) history of allergy to penicillin actually have evidence of immune-mediated hypersensitivity, and for this reason reliable confirmation of this is essential.<sup>107</sup>

In patients with allergy to beta-lactams, triple therapy with PPI, clarithromycin and metronidazole has traditionally been recommended.<sup>21</sup> In a meta-analysis conducted more than 20 years ago, treatment with PPI, clarithromycin and nitroimidazole was considered relatively effective, with mean eradication rates above 80%.<sup>108</sup> However, in a prospective Spanish study, this regimen was administered for 7 days to 12 patients allergic to penicillin and an eradication rate (by ITT) of only 58% was obtained.<sup>109</sup> In another subsequent Spanish study, in this case a multicentre study, eradication figures as low as 55% were achieved when using this same treatment in 50 patients.<sup>110</sup> The disappointing cure rates (<60%) in these Spanish studies<sup>109,110</sup> could be due, at least

in part, to the recent increase in resistance rates to both clarithromycin and metronidazole.<sup>29,45,111</sup>

A few years ago, two groups of researchers evaluated the efficacy of a regimen with PPI, tetracycline and metronidazole for 10 days in 5 and 17 patients, with penicillin allergy, obtaining eradication rates (by ITT) of 80–85%.<sup>112,113</sup> These encouraging results suggested that this triple combination (or better yet, with the addition of bismuth, which would result in a quadruple regimen) could be a better alternative for first-line treatment in the presence of penicillin allergy (mainly in areas with high resistance to metronidazole or clarithromycin). This would probably be the case because the negative effect of resistance to metronidazole is overcome by the co-administration of bismuth<sup>114</sup> and because the efficacy of this regimen is not influenced by resistance to clarithromycin.<sup>83</sup>

In this regard, the results of a prospective Spanish multicentre study have recently been updated, in which 267 patients allergic to penicillin were administered a first-line treatment of PPI, clarithromycin and metronidazole for 7 days or of PPI, bismuth, tetracycline and metronidazole for 10 days.<sup>115</sup> The eradication rate (by ITT) with the triple therapy was only 57%, being clearly higher with the quadruple regimen (74%). Adherence to treatment was 94% and 98%, respectively. Adverse effects (all mild) were reported in 14% of patients with both regimens. It was therefore concluded that, despite the fact that in areas of low resistance to clarithromycin, perhaps a triple combination with PPI, clarithromycin and metronidazole could be prescribed in patients allergic to penicillin, quadruple therapy with bismuth should be preferred in areas, such as Spain, with high resistance to clarithromycin.

Along the same lines, the results have recently been published of a Hp-EuReg study specifically aimed at analysing the experience of patients (more than 1000) allergic to penicillin.<sup>116</sup> In first-line treatment, the effectiveness of the combination of a PPI, clarithromycin and metronidazole was only 69%, while the bismuth quadruple therapy (either in its traditional format or with the single Pylera® capsule) reached 91%.

Finally, Liang et al. randomised 109 penicillin-allergic patients to receive a classic bismuth quadruple therapy (PPI, bismuth, tetracycline and metronidazole) or a modified bismuth quadruple regimen (PPI, bismuth, tetracycline and furazolidone).<sup>117</sup> Eradication rates (by ITT) were 88% and 92%, respectively, supporting the effectiveness of bismuth-containing quadruple regimens in penicillin-allergic patients.

In summary, in patients allergic to penicillin, it is recommended, in our setting, to use a quadruple regimen with bismuth (PPI, bismuth, tetracycline and metronidazole) as the first line of treatment.

**Recommendation 6.** It is not recommended to combine probiotics with eradication therapy.

100% agreement; votes: totally agree (100%). GR: strong. QE: low.

Probiotics are live microorganisms that, administered in adequate amounts, can confer beneficial health effects. Although there is some evidence in favour of the clinical usefulness of certain probiotics, the latest Clinical Practice Guide from the American Gastroenterological Association only recommends their use in the prevention of diarrhoea

due to *Clostridioides difficile* and necrotising enterocolitis in preterm newborns.<sup>118</sup> However, the heterogeneity in the methodology of the studies and the variability of the strains involved, probably grouped inadequately in many cases, could explain, at least in part, the inconsistent results obtained. The most commonly used microorganisms in probiotic formulations in clinical practice are *Lactobacillus* spp., *Bifidobacterium* and *Saccharomyces*, as well as *Bacillus*, *Streptococcus* and *Escherichia coli*. The potential beneficial effects include regulation of the intestinal microbiota, stimulation of the immune system response and inhibitory activity against *H. pylori* demonstrated *in vitro* and *in vivo*.<sup>119</sup>

Regarding eradication therapy against *H. pylori*, there is considerable scientific evidence, summarised in multiple meta-analyses, on the use of multiple probiotic formulations, which globally point to a reduction in adverse effects and, to a lesser extent, a possible improvement in eradication rates with eradication therapies.<sup>120–137</sup> However, various negative results have been published with the use of probiotics in combination with, primarily, triple therapy.<sup>138–142</sup> It is likely that these discordant results are related to the use of different strains and combinations of these, as well as different concentrations, doses and durations of treatment.<sup>143,144</sup> On the other hand, the vast majority of published studies on probiotics have evaluated their impact on the classic triple therapy, a relatively well tolerated treatment, with insufficient efficacy and which is no longer recommended as a first-line treatment in our setting.<sup>23</sup> In this context, a recent meta-analysis including 33 clinical trials and 4459 patients showed that the therapeutic benefit obtained with probiotics was greater the less effective the eradication therapy.<sup>125</sup> In fact, probiotic supplementation did not provide any therapeutic benefit when the effectiveness of the eradication therapy was greater than 80%. Moreover, in a randomised clinical trial, the usefulness of probiotics in combination with concomitant quadruple therapy, which is one of the first-line treatments currently recommended in Spain, was nil.<sup>66</sup> And neither were two recent randomised studies able to demonstrate the potential beneficial effect (in terms of eradication of *H. pylori*) of probiotics combined with bismuth quadruple therapy, which represents another of the first-line options in our setting.<sup>145,146</sup>

Finally, it should be noted that probiotics are not funded in Spain, which increases the cost of eradication therapy. In addition, it makes the quadruple therapy more complex, by adding a fifth compound. Lastly, no studies have been published that allow us to predict which patients have a higher risk of suffering side effects with antibiotic treatment, which would enable the administration of probiotics to be individualised. In any case, the use of probiotics could be considered in highly selected cases, such as in patients with poor tolerance or with side effects with previous antibiotic treatments.

In conclusion, more evidence is needed about the impact of probiotics on the effectiveness and safety of the new quadruple eradication therapies against *H. pylori* before they can be implemented in daily clinical practice. Therefore, at the moment it is not recommended to combine probiotics with eradication therapy.

**Recommendation 7.** After the failure of a first treatment that includes clarithromycin (triple or quadruple), a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended. Another option is a quadruple regimen with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth).

100% agreement; votes: totally agree (100%). GR: strong. QE: moderate.

Following the failure of clarithromycin therapy, it is conceivable that *H. pylori* was already resistant to this antibiotic (primary resistance) or that it had developed resistance (secondary) to it after a failed eradication therapy. Therefore, using clarithromycin again should be avoided. In this regard, a combined analysis of eight studies found a very low eradication rate of 46% when a treatment containing this antibiotic was repeated.<sup>147</sup>

When standard triple therapy (PPI, clarithromycin and amoxicillin – a combination that is no longer recommended) has failed, the classic quadruple therapy (PPI, bismuth, tetracycline and metronidazole) has traditionally been recommended as a rescue treatment, with which, according to a meta-analysis published in 2013, an average eradication of 78% was achieved.<sup>147</sup> Recently, a meta-analysis of nine studies using the same regimen has obtained similar results (76%).<sup>148</sup> In recent years, experience has been steadily obtained in the use of Pylera® as a rescue treatment. Moreover, an updated meta-analysis concludes that this treatment has an efficacy (by ITT) of 89% as second-line treatment, with a good safety profile.<sup>84</sup> In the same way, the experience of the Hp-EuReg is also encouraging, having confirmed the results of the aforementioned meta-analysis, reaching eradication rates of approximately 90% (by ITT), both in Europe and in Spain in particular, after the failure of a first attempt at eradication.<sup>36,88,95,149</sup>

Due to the complexity of the classic bismuth quadruple therapy and the lack of availability of tetracycline and bismuth salts in many countries, various studies have been carried out using levofloxacin as rescue treatment.<sup>150</sup> The results have been similar to those obtained with bismuth quadruple therapy, with a mean eradication of 76–79%.<sup>147,148</sup> Various meta-analyses have compared, as a second-line treatment, a triple regimen with levofloxacin versus a quadruple therapy with bismuth, and have shown similar efficacy with both regimens (or even somewhat higher with levofloxacin in some cases) and a lower incidence of adverse effects with quinolone-containing therapy.<sup>147,151–157</sup>

These promising results with levofloxacin were confirmed in a large Spanish multicentre study, in which 1000 patients, in whom a first eradication therapy with PPI, amoxicillin and clarithromycin had failed, received PPI, amoxicillin and levofloxacin for 10 days.<sup>158</sup> Eradication was achieved in 74% of the patients and, although adverse effects were reported in one fifth of the cases, none of them was serious. In this study, it was also assessed whether the efficacy decreased over time, since the resistance to quinolones in Spain seems to be increasing fairly quickly.<sup>24,27</sup> However, eradication rates remained stable over time (during the six years of the study).<sup>158</sup>

Non-bismuth quadruple therapies that include PPI, amoxicillin, clarithromycin and a nitroimidazole (mostly in a concomitant regimen) are widely used as first-line treatment today. Finding rescue therapies after the failure

of these therapies, which use key antibiotics such as clarithromycin and nitroimidazoles, is challenging. A meta-analysis has recently been carried out to evaluate which second-line treatments have been investigated after a failed eradication attempt with these therapies.<sup>159</sup> Most of the studies evaluated a rescue treatment with PPI, amoxicillin and levofloxacin, a combination with which an overall eradication rate (by ITT) of approximately 80% was obtained, after failure of a non-bismuth quadruple therapy.<sup>139,160–165</sup> This triple therapy (PPI, amoxicillin and levofloxacin) was relatively effective both after failure of sequential therapy (81%)<sup>139,161–165</sup> and concomitant therapy (77%).<sup>160,161,165</sup>

It is evident that the efficacy of triple therapy with levofloxacin can be improved (remember that currently our therapeutic objective must be to achieve an eradication efficacy equal to or greater than 90%, and we should not settle for less, regardless of whether it is an initial or rescue treatment). At the same time, as previously mentioned, the rate of resistance to quinolones seems to be increasing and this may negatively affect the efficacy of triple therapy with levofloxacin.<sup>166,167</sup> It has been suggested that the addition of bismuth could reduce this negative effect, as this drug has a synergistic effect with certain antibiotics and largely overcomes resistance to clarithromycin and levofloxacin.<sup>168,169</sup> In this regard, a recent study has shown that with the addition of bismuth (PPI, amoxicillin, levofloxacin and bismuth for 14 days) an eradication efficacy is obtained of 95% "by protocol" and 88% by ITT.<sup>169</sup> These figures were higher than those obtained with a triple therapy – without bismuth – with PPI, amoxicillin and levofloxacin. These favourable results were obtained despite a high rate of resistance to quinolones (30%), higher than that described in our setting. This quadruple therapy (PPI, amoxicillin, levofloxacin and bismuth) achieved eradication in 98% of patients with quinolone-sensitive *H. pylori* strains and, more importantly, achieved eradication in a relatively high percentage (71%) of strains resistant to levofloxacin. However, when triple therapy with levofloxacin was used, the infection was only eradicated in 38% of patients with quinolone-resistant strains.

More recently, various studies have evaluated the aforementioned quadruple combination with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth) as a second-line treatment,<sup>150</sup> as shown in Table 5, achieving generally satisfactory eradication rates.<sup>169–179</sup> Among them, a recent Spanish multicentre study administered a quadruple combination with PPI/12 h, amoxicillin (1 g/12 h), levofloxacin (500 mg/24 h) and bismuth (240 mg/12 h) for 14 days in 200 patients in whom triple therapy (PPI, clarithromycin and amoxicillin) or non-bismuth quadruple therapy had previously failed.<sup>176</sup> In total, 96% of the patients took the medication correctly. Globally, ITT eradication rates were 90%. These figures were similar regardless of previous treatment: triple therapy (88.5%) vs. sequential therapy (93.8%) vs. concomitant therapy (91.9%). Therefore, quadruple therapy with bismuth and levofloxacin for 14 days constitutes an effective second-line therapy ( $\geq 90\%$  cure), not only in patients after eradication failure with standard triple therapy but also in those with failure of quadruple therapy without bismuth.

In this regard, quadruple therapy with levofloxacin (PPI, levofloxacin, amoxicillin and bismuth) administered for at

**Table 5** Studies evaluating the efficacy of the combination of PPI, amoxicillin, levofloxacin and bismuth for the eradication of *H. pylori*.

Author	Country	No. of patients	Treatment line	Duration (days)	Eradication
Aksoy <sup>170</sup>	Turkey	111	1st	14	84%
Cao <sup>171</sup>	China	141	1st	14	83%
Bago <sup>172</sup>	Croatia	66	1st	7	86%
Fu <sup>173</sup>	China	200	1st	14	84%
Gan (a) <sup>174</sup>	China	200	1st	14	78%
Gan (b) <sup>174</sup>	China	187	1st	14	83%
Gao <sup>175</sup>	China	72	1st	10	83%
Liao <sup>169</sup>	China	80	1st	14	88%
Gisbert <sup>176</sup>	Spain	200	2nd	14	90%
Song <sup>178</sup>	China	132	2nd	14	74%
Yee <sup>179</sup>	China	51	≥2nd	7	73%
Hsu <sup>177</sup>	Taiwan	37	3rd	10	84%

"Intention-to-treat" eradication rates.

Gan (a): levofloxacin 500 mg/24 h; Gan (b): levofloxacin 200 mg/12 h; PPI: proton pump inhibitor.

least 10 days proved to be the most effective treatment in a network meta-analysis that included 26 clinical trials on second-line eradication therapies,<sup>157</sup> in accordance with the results of the previously cited meta-analysis (in which eradication reached 90% with this quadruple regimen).<sup>159</sup> In the same vein, the most up-to-date data from the Hp-EuReg show how, after failure of a first-line treatment containing clarithromycin, optimal eradication (≥90%) is obtained with a quadruple therapy with bismuth, either the traditional one (with tetracycline and metronidazole) or with levofloxacin.<sup>95,149</sup> In particular, the Spanish data from this registry confirm how eradication figures of approximately 90% can be achieved both with quadruple therapy with levofloxacin and with Pylera®.<sup>36</sup> In the latter, quadruple therapy with PPI, bismuth, tetracycline and metronidazole has achieved promising results as rescue treatment after failure of a quadruple therapy without bismuth, but experience is still limited.<sup>180,181</sup>

It should be noted that it has been estimated that eradication therapy with levofloxacin will not achieve acceptable eradication rates (≥90%) if the proportion of *H. pylori* strains resistant to this antibiotic is >25%.<sup>182</sup> In Spain, published data describe, in most cases, rates of resistance to levofloxacin that do not reach this threshold,<sup>47,49,50,183,184</sup> but it is obvious that the increase in resistance to quinolones must be monitored locally.

Regarding the duration of treatment with levofloxacin, this should be at least 10 days, and probably better of 14 days.<sup>150</sup> In this regard, three meta-analyses<sup>151–153</sup> have shown, as have three recent randomised clinical trials,<sup>166,185,186</sup> higher cure rates with regimens of 10–14 days than with treatments containing levofloxacin for only 7 days. Furthermore, two recent studies have compared the efficacy of triple therapy containing levofloxacin for 14, 10 and 7 days as rescue treatment, and have shown a higher eradication rate with the longer regimen.<sup>187</sup>

With regard to the dosage of levofloxacin, a dose of 500 mg per day is considered sufficient.<sup>150</sup> Thus, levofloxacin 500 mg/day has been shown to be equally effective, but better tolerated, than higher doses (e.g. 1000 mg/day).<sup>166,188–190</sup>

Recently, the US Food and Drug Administration and the European Medicines Agency have published several alerts on serious adverse effects of fluoroquinolones. For this reason, both agencies advise against the use of fluoroquinolones for most mild and moderate infections or those in which there is a therapeutic alternative, restricting their use to infections in which the therapeutic benefit outweighs the risks.<sup>191</sup> In this sense, taking into account the results obtained in clinical practice, we consider that, for the time being, the recommendations issued by the Conferencia Española de Consenso [Spanish Consensus Conference] on the treatment of previous *H. pylori* infection (IV)<sup>6</sup> should not be substantially modified, as well as those by other international consensus groups,<sup>25,192</sup> regarding the use of fluoroquinolones as rescue treatment after the failed eradication of *H. pylori*. That being said, it is necessary to insist on the need to make responsible use of all antibiotics – and of quinolones in particular, which in the case of *H. pylori* should be reserved for rescue therapies – to report all suspected adverse reactions and to remain attentive to possible communications from national and international health authorities on serious adverse effects of these drugs.<sup>191</sup>

**Recommendation 8.** After the failure of a first treatment with a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple regimen with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth) is recommended.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: strong. QE: low.

After an eradication failure with bismuth quadruple therapy (PPI, bismuth, tetracycline and metronidazole), any treatment could theoretically be used, including the repetition of the same quadruple therapy but with higher doses and longer duration of metronidazole, given that the rate of acquired resistance after the use of amoxicillin, bismuth or tetracycline is negligible (<3%) and resistance to metronidazole could be overcome, at least partially, in this way.<sup>22</sup> However, it seems logical not to repeat a treatment that has already failed.<sup>37</sup> It also seems reasonable to assume that if quadruple therapy with bismuth has been used as the first option, it may be due to the existence of a high

rate of resistance to clarithromycin (which reduces the efficacy of standard triple therapy) or a high rate of combined resistance to clarithromycin and metronidazole (which is associated with lower efficacy of non-bismuth quadruple therapies).<sup>22</sup> In this sense, after a first eradication attempt with metronidazole has failed, there is a high probability that *H. pylori* is resistant to this antibiotic (either because it had previous primary resistance or because it developed secondary resistance after treatment). In any case, as is well known, the presence of dual resistance – to clarithromycin and to metronidazole – greater than 15% would significantly limit the efficacy of concomitant quadruple therapy. Thus, the use of a second-line treatment containing clarithromycin ± metronidazole after failure of a quadruple therapy with bismuth would probably not be the best option (although it could theoretically be considered to administer a quadruple combination with PPI, amoxicillin, clarithromycin and bismuth, although experience of this as a rescue treatment is very limited).<sup>23,97</sup>

On the contrary, it is well known that levofloxacin therapy is effective as a second-line treatment after failure of clarithromycin treatment<sup>150</sup>; therefore, this would seem more recommendable after the eradication failure of a quadruple regimen with bismuth. However, experience after failure of a quadruple therapy with bismuth in general, and with the administration of a rescue treatment with levofloxacin in particular, is remarkably limited. Studies that have evaluated the efficacy of a third-line treatment combining PPI, amoxicillin and levofloxacin for the eradication of *H. pylori* after failure of two treatments, the second line being the quadruple regimen with bismuth, are reviewed in recommendation 11 (obtaining an efficacy between 60% and 85%, with a mean of approximately 75%).

As previously mentioned (see recommendation 7, devoted to rescue treatment after failure of clarithromycin therapies), the addition of bismuth to triple therapy with levofloxacin has achieved promising results, so it would therefore be the choice. In this regard, the results of the Hp-EuReg support this recommendation, by demonstrating that, after the failure of a quadruple therapy with bismuth, a second-line quadruple regimen with quinolones (i.e. PPI, levofloxacin, amoxicillin and bismuth), administered for 14 days, reaches optimal eradication figures ( $\approx 90\%$ ).<sup>149</sup>

**Recommendation 9.** Rescue treatment in patients allergic to penicillin:

- a) After the failure of a first triple therapy (PPI, clarithromycin and metronidazole), it is suggested to use a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole). GR: weak. QE: very low.
- b) After the failure of a first quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple therapy with PPI, levofloxacin, clarithromycin and bismuth is suggested.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: weak. QE: very low.

The eradication of *H. pylori* in penicillin-allergic patients is challenging, especially in those in whom a previous eradication attempt has already failed. In a Spanish pilot study, 15 penicillin-allergic patients in whom a first treatment with PPI, clarithromycin and metronidazole had failed received a

second treatment with PPI, clarithromycin and levofloxacin for 10 days.<sup>110</sup> Adherence to treatment was complete in all cases. Adverse effects, which were all mild, were reported in 20% of the patients. The eradication rate (by ITT) was 73%.

More recently, in a Spanish multicentre study, 267 penicillin-allergic patients received first-line treatment with PPI, clarithromycin and metronidazole or bismuth quadruple therapy (PPI, bismuth, tetracycline and metronidazole); and as rescue therapies, bismuth quadruple therapy or a regimen with PPI, clarithromycin and levofloxacin for 10 days.<sup>115</sup> The eradication rate (by ITT) with PPI, clarithromycin and levofloxacin was 64%, both after failure of PPI, clarithromycin and metronidazole and of first-line quadruple therapy with bismuth, and adherence was 88–100%, with adverse effects (all mild) in 23–29% of patients. Therefore, the authors concluded that a triple therapy with PPI, clarithromycin and levofloxacin represents a second-line alternative in patients with a penicillin allergy.

In this regard, the results of the Hp-EuReg focusing specifically on patients allergic to penicillin have recently been published.<sup>116</sup> In second-line treatment, after the failure of a combination of a PPI, clarithromycin and metronidazole, two rescue options showed similar efficacy: a quadruple therapy with PPI, bismuth, tetracycline and metronidazole (78%), and a triple combination with PPI, clarithromycin and levofloxacin (71%).<sup>116</sup>

The few studies that have evaluated the various empirically prescribed rescue eradication therapies (without studying bacterial susceptibility) in patients with penicillin allergy are summarised in Table 6.<sup>109,110,112,115,116,193–195</sup> From these it can be concluded that, in patients allergic to penicillin, after failure of a triple therapy (PPI, clarithromycin and metronidazole, a combination that is currently no longer recommended), it could be suggested to use a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole); whereas, after the failure of a first quadruple therapy with bismuth, a triple therapy with PPI, levofloxacin and clarithromycin could be considered. However, since, as previously discussed in other recommendations, the addition of bismuth to various triple therapies seems to increase their efficacy,<sup>23</sup> it seems more reasonable to suggest, although there is no direct evidence to support it, the use of a quadruple therapy adding this last drug (PPI, levofloxacin, clarithromycin and bismuth).

**Recommendation 10.** After the failure of a first treatment with clarithromycin and a second treatment with levofloxacin, a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) is recommended.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: strong. QE: low.

Following failure of a triple or quadruple combination with clarithromycin, as previously reviewed, levofloxacin therapy is frequently recommended.<sup>150</sup> On occasions, this second treatment also fails, and in these cases a quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) is usually prescribed.<sup>15</sup> The choice of rescue treatment depends on the drugs that have been used in the previous eradication attempts. Since repeating the same antibiotic is not recommended (with the well-known exceptions of bismuth, amoxicillin and, to a lesser extent, metronidazole), bismuth quadruple therapy currently seems

**Table 6** Studies evaluating empirically prescribed *H. pylori* eradication rescue therapies (without bacterial susceptibility study) in patients with penicillin allergy.

Author	Country	Design	Rescue treatment	Therapeutic regimen	Duration (days)	No. of patients	Eradication
Ono <sup>193</sup>	Japan	R	2nd° and 3rd°	PPI + C + M	7	3	33%
Ono <sup>193</sup>	Japan	R	2nd° and 3rd°	V + C + M	7	1	100%
Rodríguez <sup>112</sup>	Puerto Rico	R	2nd°	PPI + T + M	10	3	100%
Gisbert <sup>109</sup>	Spain	P	2nd°	RBC + T + M	7	17	47%
Gisbert <sup>115</sup>	Spain	P	2nd°	PPI + B + T + M	10	24	37%
Gisbert <sup>110</sup>	Spain	P	2nd°	PPI + C + L	10	15	73%
Gisbert <sup>115</sup>	Spain	P	2nd°	PPI + C + L	10	64	64%
Nyssen <sup>116</sup>	Spain	P	2nd	PPI + B + T + M	10–14	69	78%
Nyssen <sup>116</sup>	Spain	P	2nd	PPI + C + L	10–14	20	71%
Furuta <sup>194</sup>	Japan	R	2nd°	PPI + M + S	7–14	10	100%
Mori <sup>195</sup>	Japan	P	2nd°	PPI + M + S	10	19	84%
Gisbert <sup>115</sup>	Spain	P	3rd°	PPI + B + T + M	10	3	100%
Gisbert <sup>115</sup>	Spain	P	3rd°	PPI + C + L	10	3	33%
Gisbert <sup>109</sup>	Spain	P	3rd°	PPI + C + R	10	9	11%
Gisbert <sup>115</sup>	Spain	P	3rd°	PPI + C + R	10	7	14%
Nyssen <sup>116</sup>	Spain	P	3rd°	PPI + B + T + M	10–14	78	75%
Furuta <sup>194</sup>	Japan	R	3rd°	PPI + M + S	7–14	7	100%
Mori <sup>195</sup>	Japan	P	3rd°	PPI + M + S	10	5	40%
Gisbert <sup>109</sup>	Spain	P	4th°	PPI + C + L	10	2	100%
Gisbert <sup>115</sup>	Spain	P	4th°	PPI + C + L	10	2	100%
Gisbert <sup>115</sup>	Spain	P	4th°	PPI + C + R	10	2	50%

“Intention-to-treat” eradication rates.

Design: P (prospective), R (retrospective).

B: bismuth; C: clarithromycin; PPI: proton pump inhibitor; L: levofloxacin; M: metronidazole; R: rifabutin; RBC: ranitidine bismuth citrate; S: sitafloxacin; T: tetracycline; V: vonoprazan.

the most appropriate option, since it fundamentally avoids the re-administration of clarithromycin and levofloxacin.<sup>15</sup>

A few years ago, a Spanish multicentre study was conducted in which the efficacy of bismuth quadruple therapy as a third-line treatment was evaluated.<sup>196</sup> A third eradication therapy was administered with PPI (at standard doses every 12 h), bismuth subcitrate (120 mg/6 h or 240 mg/12 h), tetracycline (between 250 mg/8 h and 500 mg/6 h) and metronidazole (between 250 mg/8 h and 500 mg/6 h) for 7–14 days in 200 patients. Eradication (by ITT) was deficient (65%), probably due, at least in part, to the insufficient dose and duration of the antibiotic treatment.<sup>196</sup> Subsequently, other studies have been carried out, using the Pylera® single capsule formulation (and therefore with a homogeneous dose and duration of its components), and the meta-analysis of this as a third-line treatment has calculated an average eradication of 82%.<sup>84</sup> Among these studies, one carried out in Spain stands out, which included 101 patients with previous failure of triple therapy with clarithromycin and triple therapy with levofloxacin, with Pylera® being effective in 80% of cases (by ITT).<sup>197</sup> More recently, Hp-EuReg data focused on the third line of treatment have confirmed these encouraging results, describing eradication figures of 88% when evaluating 275 patients treated with Pylera®.<sup>82</sup> These high eradication figures (of approximately 90%) have been confirmed in various updated analyses of the Hp-EuReg, carried out in 2020 and 2021, on the efficacy of Pylera® as third-line treatment.<sup>88,95</sup>

One possibility in the event of failure of two eradication therapies is to perform a culture and antibiogram to select the most appropriate third-line antibiotic combination based on bacterial susceptibility. Although this "targeted" treatment option is recommended in some consensus guidelines, its advantage over empirical treatment has not been confirmed.<sup>13</sup> The sub-analysis of the studies that included second-line treatments in a recent meta-analysis,<sup>11</sup> and a review of the literature comparing the efficacy of empirical treatment versus treatment based on antibiotic susceptibility,<sup>12</sup> could not demonstrate statistically significant differences between both strategies. These results coincide with those described in a subsequent meta-analysis.<sup>198</sup> No randomised clinical trials were identified that compared empirical versus third-line antibiogram-directed treatment, but the mean eradication rate of studies using the culture-based strategy was only 72%.<sup>11</sup> Finally, in an updated meta-analysis carried out in 2020, when all the rescue therapies were included (13 studies), similar results were demonstrated with both strategies – empirical and based on microbial susceptibility –, both when including all studies as well as only the randomised clinical trials.<sup>14</sup>

It has been previously specified that the comments included in this consensus document are based on the assumption that the antibiotic susceptibility of the particular patient is unknown. In addition, most of the authors of this document believe that there are arguments for not having to systematically perform a culture before indicating a third eradication therapy, but that, on the contrary, it is perfectly feasible and appropriate to administer an empirical treatment after the failure of a second attempt. This recommendation is evidence-based and also takes into account that culturing *H. pylori* is a technique available in few centres, which requires an invasive test such as

upper gastrointestinal endoscopy (since detection by PCR in faeces has not yet been sufficiently evaluated), with an average sensitivity of less than 90% and with considerable discrepancy between the results obtained *in vitro* and the eradication rate *in vivo*.<sup>13,199</sup> Furthermore, culture provides useful information only about some antibiotics already used in previous first-line (clarithromycin and metronidazole) and second-line (levofloxacin) eradication therapies, which, by definition, should not be reused.

In summary, it is concluded that the empirical quadruple rescue treatment with bismuth is a valid alternative after failure of a treatment with clarithromycin and another with levofloxacin.

**Recommendation 11.** After the failure of a first treatment with clarithromycin and a second-line quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole), a quadruple therapy with levofloxacin (PPI, amoxicillin, levofloxacin and bismuth) is recommended.

100% agreement; votes: totally agree (100%). GR: strong. QE: low.

After the failure of triple or quadruple therapy with clarithromycin, quadruple therapy with PPI, bismuth, tetracycline and metronidazole is frequently recommended.<sup>5,15</sup> When this second treatment also fails, with the intention of not re-administering clarithromycin or metronidazole, it has been suggested to prescribe a triple regimen with PPI, amoxicillin and levofloxacin.<sup>5,15</sup>

However, there has been little experience in the use of quinolones after the failure of two eradication therapies. A few years ago a Spanish multicentre study was published evaluating the efficacy of triple therapy with levofloxacin as third-line treatment, achieving eradication in approximately 70% of cases.<sup>200</sup> These results have recently been confirmed in a larger national multicentre study, including a total of 200 patients.<sup>201</sup> Patients were included in whom a first treatment with PPI, amoxicillin and clarithromycin had failed, as well as a second treatment with bismuth quadruple therapy (PPI, bismuth, tetracycline and metronidazole). A third eradication therapy with PPI, amoxicillin and levofloxacin was administered for 10 days. The eradication rate (by ITT) was 68%. Other authors have obtained similar or slightly better results with this third-line treatment with levofloxacin, with eradication rates that have ranged between 60% and 84% (with a mean of 75%), as summarised in Table 7.<sup>177,200–206</sup> Among these studies, the best results (with eradication rates of 84%) were obtained when bismuth was added to triple treatment with levofloxacin, making it quadruple,<sup>177,205</sup> similar to that previously described for second-line levofloxacin therapy.<sup>176</sup>

Therefore, it is concluded that the empirical quadruple rescue treatment with PPI, amoxicillin, levofloxacin and bismuth constitutes a third-line alternative after the failure of two previous eradication therapies containing key antibiotics such as amoxicillin, clarithromycin, metronidazole and tetracycline.

**Recommendation 12.** After the failure of a first quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole) and a second-line treatment with levofloxacin, a concomitant quadruple therapy (PPI, amoxicillin, clarithromycin and metronidazole) is suggested.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: weak. QE: very low.

**Table 7** Studies evaluating the efficacy of a third-line combination with PPI, amoxicillin and levofloxacin ( $\pm$  bismuth) for the eradication of *H. pylori* after two eradication failures.

Author and year of publication	No. of patients	Previous treatments (failed)	Duration (days)	Eradication
Gatta <sup>202</sup> , 2005	151	1st <sup>o</sup> ) IBP + C + A o M 2nd <sup>o</sup> ) IBP + C + A o M; Q	10	76%
Gisbert <sup>200</sup> , 2006	100	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	10	60%
Gisbert <sup>203</sup> , 2006	20	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	10	85%
Hsu*, <sup>177</sup> 2008	37	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	10	84%
Rokkas <sup>204</sup> , 2009	30	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	10	70%
Gisbert <sup>201</sup> , 2012	200	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	10	68%
Burgos-Santamaría <sup>205</sup> , 2019	65	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	7-14	75%
Burgos-Santamaría*, <sup>205</sup> 2019	19	1st <sup>o</sup> ) IBP + C + A 2nd <sup>o</sup> ) Q	14	84%
Burgos-Santamaría <sup>206</sup> , 2020	39	1st <sup>o</sup> ) IBP + C + A $\pm$ M 2nd <sup>o</sup> ) Q	10-14	74%
Burgos-Santamaría*, <sup>206</sup> 2020	28	1st <sup>o</sup> ) IBP + C + A $\pm$ M 2nd <sup>o</sup> ) Q	14	75%

"Intention-to-treat" eradication rates.

A: amoxicillin; C: clarithromycin; PPI: proton pump inhibitor; M: metronidazole; Q: quadruple therapy with bismuth (PPI, bismuth, tetracycline and metronidazole).

\* Bismuth added to triple therapy with PPI, amoxicillin and levofloxacin.

In this case (failure of a first quadruple therapy with bismuth and a second-line treatment with levofloxacin), since clarithromycin has not been used previously, it is suggested to use a concomitant quadruple therapy, which is precisely one of the first-line treatments of choice in our setting. It should be mentioned that this recommendation is not based on any direct evidence, but is established according to theoretical assumptions, and due to the absence of other effective therapeutic alternatives. Thus, although it has previously been argued that concomitant therapy would probably not be the best option after the failure of a quadruple therapy with bismuth (see recommendation 8), in this case we do not have a better option (especially if initially opting for bismuth quadruple therapy and not concomitant quadruple therapy was not due to a high rate of resistance to clarithromycin).

As an alternative, the combination of PPI, clarithromycin, amoxicillin and bismuth could be suggested, with which good results have been obtained in some studies,<sup>23</sup> although experience in our setting is very limited.<sup>97</sup> Another option is to use rifabutin, although this antibiotic is usually reserved, as detailed below, for a fourth line of treatment.<sup>207,208</sup>

**Recommendation 13.** After the failure of a third treatment, it is suggested to carefully reevaluate the need to eradicate the infection and, where appropriate, to indicate a fourth-line treatment with rifabutin.

Agreement 92.8%; votes: totally agree (92.8%); somewhat disagree (7.1%). GR: weak. QE: very low.

Occasionally, *H. pylori* infection persists despite having administered three eradication therapies.<sup>199</sup> Since it is unknown whether the benefit obtained from the potential

eradication of *H. pylori* outweighs the safety problems with more complex lines of treatment, in these patients the indication for eradication therapy and the possibility of stopping (if necessary) maintenance antisecretory treatment, should be individually reevaluated. Obviously, the decision to prescribe a fourth line of treatment will be clearer when the benefit of *H. pylori* eradication is greater, as is the case in patients with a peptic ulcer (especially if they have suffered previous complications) or a gastric MALT lymphoma.

A recent review of the literature has evaluated the role of rifabutin – an antibiotic that has high *in vitro* activity against *H. pylori* – in the treatment of this infection.<sup>208</sup> The mean rate of resistance of *H. pylori* to rifabutin (calculated from 39 studies and almost 10,000 patients) was less than 1%. When only those studies that included patients without prior eradication therapy were considered, this figure was even lower (0.07%). Overall, the mean eradication rate (by ITT) with the combinations that included rifabutin (3000 patients analysed) was 73%. Specifically, the corresponding figures for fourth-line rifabutin therapies were approximately 70%.<sup>115,205,209-215</sup> For the treatment of *H. pylori* infection, most studies have prescribed 300 mg/day of rifabutin, a dose that appears to be more effective than 150 mg/day. The optimal duration of treatment has not been established, but it is generally recommended to administer it for 10–12 days. The mean incidence of adverse effects was 15%; myelotoxicity was the most relevant, although exceptional. To date, all patients have recovered from leukopenia within a few days after completing treatment, and no infections or other complications associated with myelotoxicity have been reported.<sup>208</sup>

These results have been confirmed in a large Spanish multicentre study, in which the efficacy of a fourth empirical rescue treatment with rifabutin was evaluated in patients in whom three eradication attempts had previously failed (the first with PPI, clarithromycin and amoxicillin; the second with a quadruple therapy with PPI, bismuth, tetracycline and metronidazole; and the third with PPI, amoxicillin and levofloxacin).<sup>213</sup> A fourth eradication therapy with PPI, amoxicillin (1 g/12 h) and rifabutin (150 mg/12 h) was administered for 10 days to 100 patients, and the eradication rate (by ITT) was 50%. Adverse effects were reported in 30% of patients; myelotoxicity (always mild) was found in 4% of patients and resolved spontaneously in all cases after completion of treatment. Lastly, the most recent data from the Hp-EuReg have confirmed somewhat higher eradication figures, of 65% in the fourth line of treatment.<sup>216</sup>

Finally, although the evidence in this respect is very limited,<sup>217–219</sup> in the face of multiple eradication failures, combining bismuth with rifabutin could be considered,<sup>217–219</sup> with the intention of increasing eradication efficacy. In this regard, Ciccaglione et al. reported that the addition of bismuth to a triple therapy that included a PPI, amoxicillin and rifabutin in patients receiving a third line of treatment, resulted in a therapeutic gain of 30% compared to rifabutin-based triple therapy.<sup>219</sup> Finally, this rifabutin regimen with bismuth has recently been evaluated in the context of the Hp-EuReg, where various empirical third-line and subsequent rescue therapies were analysed, obtaining an efficacy (by ITT) with PPI, rifabutin, amoxicillin and bismuth of approximately 60%.<sup>206</sup>

Finally, as a fourth line of treatment, a combination of a PPI and amoxicillin could also be suggested, both at high doses (e.g. omeprazole 40 mg/8 h and amoxicillin 1 g/8 h for 14 days). However, although this dual combination has obtained good results in some countries (mostly Asian),<sup>220,221</sup> its efficacy has not been confirmed in our setting.

In summary, after the failure of a third treatment, it is recommended to carefully evaluate the need for eradication and the possibility of stopping maintenance antisecretory therapy. If eradication is considered appropriate, it is recommended to individually assess the need for a fourth line of treatment, for example, with rifabutin (probably together with bismuth, in addition to amoxicillin), with strict control and monitoring of the patient.

**Recommendation 14.** In patients with uncomplicated duodenal ulcer who do not require non-steroidal anti-inflammatory drugs/aspirin, it is not recommended to continue antisecretory therapy after completing the *H. pylori* eradication therapy.

100% agreement; votes: totally agree (100%). GR: strong. QE: high.

Initially, most authors who used PPI in eradication therapies for uncomplicated duodenal ulcer disease (without gastrointestinal bleeding or perforation) extended these drugs for 2–4 weeks after the conclusion of antibiotic treatment, with the aim of "ensuring" ulcer healing.<sup>222</sup> However, it has been proven that to obtain a high rate of ulcer healing in these patients, the use of a PPI limited to the period of administration of antibiotics is sufficient in the context of eradication therapy. Thus, a systematic review of the medical literature identified 24 studies, including a total of 2378 patients, in which ulcer healing with a PPI plus two antibiotics

for 7 days was evaluated.<sup>223</sup> The mean healing rate (by ITT) was 86% when considering all patients (both with successful and failed eradication of *H. pylori*). This figure rose to 95% when only those patients in whom the infection had been eradicated were included. The meta-analysis of the six randomised studies<sup>224–229</sup> that compared efficacy in terms of ulcer healing when administering a PPI plus two antibiotics for 7 days versus the same treatment combined with a PPI for a further 2–4 weeks,<sup>223</sup> confirmed the healing of the ulcer in 91% and 92% of cases, respectively. The odds ratio (OR) for this comparison was 1.11 (95% confidence interval [CI] 0.71–1.74), with the results being homogeneous. Finally, when a sub-analysis was performed including only patients with duodenal ulcer, the results were similar (OR 1.14, with a 95% CI of 0.71–1.84). After the publication of this meta-analysis, two additional randomised studies have been carried out, with similar results.<sup>230,231</sup>

In summary, it is concluded that to obtain a high healing rate of uncomplicated duodenal ulcer in patients who do not take non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, the use of PPI during the period of administration of antibiotics is sufficient. However, in the case of complicated duodenal ulcers (gastrointestinal bleeding, perforation), it is prudent to administer antisecretors until eradication of *H. pylori* is confirmed.

**Recommendation 15.** In patients with gastric ulcers who do not require NSAIDs/aspirin, it is recommended to maintain the antisecretory therapy for 4–8 weeks after the end of the *H. pylori* eradication therapy.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: strong. QE: moderate.

There are two reviews of the medical literature published more than a decade ago that provide arguments in favour of not prolonging antisecretory therapy in patients with gastric ulcer, in keeping with the attitude adopted with duodenal ulcer. The first concludes that "eradication of *H. pylori* induces greater healing of ulcerative lesions regardless of whether they are duodenal or gastric".<sup>232</sup> The other systematic review concludes that "eradication of *H. pylori* heals both duodenal and gastric ulcers, with a similar percentage of healing".<sup>233</sup> From these data, it would appear that the healing rate with *H. pylori* eradication therapy would be similar for gastric and duodenal ulcers.

However, more recent studies suggest the need to prolong antisecretory therapy, especially in gastric ulcers larger than 1 cm. A first study documented the healing of 100% of gastric ulcers smaller than 1 cm at 8 weeks after the administration of an eradication therapy for 2 weeks.<sup>234</sup> This healing rate was considerably reduced when the ulcers were greater than 1 cm, and it is important to note that all the unhealed lesions at 8 weeks did so after additional treatment with PPI. One of the studies, with a randomised design, which provides very relevant information on this topic, evaluated gastric ulcer healing after eradication therapy for one week or a PPI for 8 weeks.<sup>235</sup> It was possible to verify how the healing rate at 8 weeks of eradication therapy decreased exponentially according to the size of the ulcer (89% for ulcers <1 cm, 54% for ulcers between 1 and 1.4 cm, and 5% for those equal to or greater than 1.5 cm); while it was significantly higher in the group treated with a PPI for 8 weeks (100% for ulcers < 1 cm, 77% for ulcers between 1 and 1.4 cm, and 77% for those equal to or greater than 1.5 cm).<sup>235</sup>

More recently, another randomised study was published comparing the administration of eradication therapy on its own versus this being followed by PPI for 3 weeks.<sup>236</sup> Gastric ulcer healing at 4 weeks was lower in patients treated with triple therapy alone, without a subsequent PPI (64% vs. 82%). Likewise, in patients with unhealed gastric ulcers, an additional 4-week course of a PPI (esomeprazole) increased the percentage of healing to 89–96 %. It should be noted that this study suffers from certain methodological deficiencies, such as the exclusion of patients with ulcers of a size >2 cm and an excessively early endoscopic control of healing (at 4 weeks) for a gastric ulcer.

Finally, a recent Japanese study randomised 115 gastric ulcer patients stratified according to the size of the lesion (<0.5 cm, 0.5–1.5 cm and >1.5 cm) to receive eradication therapy (for one week) plus 7 weeks of a PPI versus eradication therapy plus 7 weeks of a cytoprotective agent.<sup>231</sup> Ulcer healing rates at 8 weeks were significantly higher in the eradication plus PPI group. In agreement with previous studies, the results of ulcer healing with eradication therapy plus PPI were superior for gastric ulcers >1.5 cm (85% vs. 43%).

In summary, the available evidence points to a higher rate of ulcer healing with eradication therapy followed by PPI for gastric ulcers associated with *H. pylori* infection. In all the previously reported studies,<sup>231,235,236</sup> an absence of healing of up to 20% was found with the isolated eradication therapy, this failure being higher for larger ulcers. Therefore, it is recommended that, after finishing the eradication therapy, antisecretory therapy be extended between 4 and 8 weeks in gastric ulcers, especially in those larger than 1 cm.

**Recommendation 16.** In patients with gastrointestinal bleeding from peptic ulcer, the eradication of *H. pylori* eliminates practically all relapses. Therefore, once eradication is confirmed and if the patient is not taking non-steroidal anti-inflammatory drugs/aspirin, it is recommended not to administer maintenance treatment with antisecretory drugs.

100% agreement; votes: totally agree (92.8%); strongly agree (7.1%). GR: strong. QE: high.

Peptic ulcer is the first cause of upper gastrointestinal bleeding and *H. pylori* infection is the main aetiological factor in gastroduodenal ulcer disease.<sup>237</sup> Long-term maintenance antisecretory therapy was traditionally the standard treatment to prevent recurrent bleeding in patients with a previous episode of gastrointestinal bleeding from peptic ulcer. Although it is widely known that the eradication of *H. pylori* is associated with a drastic reduction in ulcer recurrence, until relatively recently the efficacy of eradication therapy in preventing recurrent bleeding from peptic ulcer was unknown.

A meta-analysis has been published, following the Cochrane Collaboration methodology, in which the efficacy of *H. pylori* eradication therapy was compared with antisecretory therapy for the prevention of recurrent bleeding from peptic ulcer.<sup>238,239</sup> In a first sub-analysis, seven studies were included, with a total of 578 patients: the average percentage of recurrent bleeding in the eradication therapy group was 2.9% and in the group without eradication therapy or maintenance antisecretory drugs it was 20% (OR 0.17; 95% CI 0.10–0.32). In a second sub-analysis, three studies were included, with a total of 470 patients: the average

percentage of recurrent bleeding in the group that received eradication therapy was 1.6% and in the group in which eradication therapy was not prescribed, but maintenance antisecretory drugs were prescribed, it was 5.6% (OR 0.24; 95% CI 0.09–0.67).

Several studies have evaluated the incidence of recurrent bleeding in patients with confirmed *H. pylori* eradication and who were followed up without administering maintenance antisecretory therapy.<sup>240–259</sup> Given that the duration of follow-up varies considerably between the different studies, the follow-up periods of each one have been taken into account and we have calculated the respective annual incidence of recurrent bleeding (per patient and year of follow-up). As such, the global follow-up was 1913 patient years, and 13 episodes of recurrent bleeding were detected among the patients in whom the bacterium was eradicated. Thus, annual recurrence is only 0.88% per patient and year of follow-up.<sup>6</sup>

These favourable results have been confirmed in a Spanish multicentre study, which prospectively included 1000 patients with gastrointestinal bleeding due to gastroduodenal ulcer in whom *H. pylori* infection was eradicated and, subsequently, antisecretory therapy was not prescribed.<sup>260</sup> Three episodes of recurrent bleeding were detected at one year of follow-up (in two cases after ingestion of NSAIDs and in the other after reinfection by *H. pylori*), and another two episodes at two years (one after ingestion of NSAIDs and the other after reinfection by *H. pylori*). The cumulative incidence of rebleeding was 0.5% and the incidence rate was 0.15% per patient year.

The above results indicate that the treatment of *H. pylori* infection is more effective than antisecretory treatment (either with or without maintenance antisecretory drugs) in preventing recurrent bleeding from peptic ulcer. Consequently, the presence of *H. pylori* infection should be evaluated in all patients with gastrointestinal bleeding from peptic ulcer (early,<sup>261</sup> ideally during the hospital admission itself<sup>262</sup>) and eradication therapy prescribed to those who are infected. Once eradication has been confirmed (which should always be done, and without delay<sup>263</sup>), it is not necessary to administer maintenance treatment with antisecretory drugs (if the patient does not require NSAIDs), since the eradication of *H. pylori* eliminates practically all recurrent bleeding. However, it seems prudent in the case of a peptic ulcer with complications (e.g. gastrointestinal bleeding) to administer antisecretory therapy until eradication of *H. pylori* is confirmed.

## Conflicts of interest

J. Alcedo, J. Amador, L. Bujanda, X. Calvet, M. Castro-Fernández, E. Gené, A. Lanas, A.J. Lucendo, J. Molina-Infante, A. Pérez-Aisa and I. Puig declare that they have no conflict of interest.

L. Fernández-Salazar has carried out teaching activities for Janssen, Norgine, Salvat and Tillots.

J.P. Gisbert has provided scientific advice and support for research and/or training activities for Mayoly, Allergan, Diasorin, Gebro Pharma and Richen.

O.P. Nyssen has provided research support for Mayoly and Allergan.

## References

1. Sainz R, Borda F, Dominguez E, Gisbert JP. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. Rev Esp Enferm Dig. 1999;91:777–84.
2. Gisbert JP, Calvet X, Gomollon F, Sainz R. [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference]. Med Clin (Barc). 2000;114:185–95.
3. Mones J, Gisbert JP, Borda F, Dominguez-Munoz E. Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig. 2005;97:348–74.
4. Gisbert JP, Calvet X, Gomollon F, Mones J. [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]. Med Clin (Barc). 2005;125:301–16.
5. Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol. 2013;36:340–74.
6. Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. [IV Spanish Consensus Conference on Helicobacter pylori infection treatment]. Gastroenterol Hepatol. 2016;39:697–721.
7. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
8. Gisbert JP, Alonso-Coello P, Pique JM. [How can we find, design, evaluate and use clinical practice guidelines?]. Gastroenterol Hepatol. 2008;31:239–57.
9. Dalkey N. Experimental study of group opinion-Delphi method. Features. 1969;1:408–26.
10. Singh H, Leontiadis GI, Hookey L, Enns R, Bistritz L, Rioux LC, et al. Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines. Can J Gastroenterol Hepatol. 2014;28:473–80.
11. Lopez-Gongora S, Puig I, Calvet X, Villoria A, Baylina M, Munoz N, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother. 2015;70:2447–55.
12. Puig I, López-Góngora S, Calvet X, Villoria A, Baylina M, Sanchez-Delgado J, et al. Systematic review: third-line susceptibilityguided treatment for Helicobacter pylori infection. Ther Adv Gastroenterol. 2015;70:2447–55.
13. Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therap Adv Gastroenterol. 2020;13, 1756284820968736.
14. Espada M, Nyssen OP, Gisbert JP. Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis. United Eur Gastroenterol J. 2021, in press.
15. Gisbert JP. [Rescue therapy after Helicobacter pylori eradication failure]. Gastroenterol Hepatol. 2011;34:89–99.
16. Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: a cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain—results of the Hp-breath initiative. Helicobacter. 2020;25, e12693.
17. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–67.
18. Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection—the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9:1–2.
19. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167–80.
20. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.
21. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–64.
22. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12, 177–86, e173; Discussion e112–173.
23. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of *H. pylori* eradication therapies. Helicobacter. 2017;22.
24. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155, 1372–82, e1317.
25. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2016;66:6–30.
26. Munoz-Gomez P, Jordan-Castro JA, Abanades-Tercero M, Blanco-Gonzalez JJ, Andres Esteban EM, Valle-Munoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter. 2018;23.
27. Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021, gutjnl-2021-324032. Online ahead of print.
28. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255–68.
29. Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007–2012)]. Gastroenterol Hepatol. 2013;36:375–81.
30. Cuadrado-Lavin A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavia M, Fernandez-Forcelledo JL, et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015;70:2376–81.
31. Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendiarte U, et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380–4.
32. Campillo A, Amorena E, Ostiz M, Kutz M, La Iglesia M. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. Gastroenterol Hepatol. 2016;39:584–9.
33. Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M. [Quadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. Med Clin (Barc). 2016;147:199–201.
34. Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for *H. pylori*

- eradication: a phase IV pilot clinical trial. *Gastroenterol Hepatol.* 2017;40:658–62.
35. McNicholl AG, O'Morain CA, Megraud F, Gisbert JP. As Scientific Committee of the Hp-Eureg on behalf of the National C. Protocol of the European Registry on the management of *Helicobacter pylori* infection (Hp-EuReg). *Helicobacter.* 2019;24:e12630.
  36. Caldas M, Perez-Aisa A, Castro-Fernandez M, Bujanda L, Lucendo AJ, Rodrigo L, et al. European Registry on *Helicobacter pylori* Management: effectiveness of first and second-line treatment in Spain. *Antibiotics (Basel).* 2020;10.
  37. Nyssen OP, Vaira D, Tepes B, Kupcinskas L, Bordin D, Perez-Aisa A, et al. Room for Improvement in the treatment of *Helicobacter pylori* infection: lessons from the European Registry on *H. pylori* Management (Hp-EuReg). *J Clin Gastroenterol.* 2021. Publish Ahead of Print. doi: 10.1097/MCG.0000000000001482. Online ahead of print.
  38. McNicholl AG, Amador J, Ricote M, Canones-Garzon PJ, Gene E, Calvet X, et al. Spanish primary care survey on the management of *Helicobacter pylori* infection and dyspepsia: information, attitudes, and decisions. *Helicobacter.* 2019;24:e12593.
  39. Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. *Aliment Pharmacol Ther.* 2021;53:794–809.
  40. Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line *Helicobacter pylori* eradication therapy: systematic review and meta-analysis. *Digestion.* 2020;1–7.
  41. Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for *Helicobacter pylori* eradication: a meta-analysis of randomized clinical trials. *Biomed Res Int.* 2019;2019:9781212.
  42. Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of *Helicobacter pylori*. *Helicobacter.* 2018;23:e12495.
  43. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for *Helicobacter pylori* eradication therapy: is superiority an illusion? *Helicobacter.* 2017;22:e12438.
  44. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on *Helicobacter pylori* eradication. *Aliment Pharmacol Ther.* 2017;46:106–14.
  45. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirsch AM, et al. *Helicobacter pylori* resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut.* 2013;62:34–42.
  46. Montes M, Villalon FN, Eizaguirre FJ, Delgado M, Munoz-Seca IM, Fernandez-Reyes M, et al. *Helicobacter pylori* infection in Children. Antimicrobial resistance and treatment response. *Helicobacter.* 2015;20:169–75.
  47. Navarro-Jarabo JM, Fernandez-Sanchez F, Fernandez-Moreno N, Hervas-Molina AJ, Casado-Caballero F, Puente-Gutierrez JJ, et al. Prevalence of primary resistance of *Helicobacter pylori* to clarithromycin and levofloxacin in Southern Spain. *Digestion.* 2015;92:78–82.
  48. Macias-Garcia F, Llovo-Taboada J, Diaz-Lopez M, Baston-Rey I, Dominguez-Munoz JE. High primary antibiotic resistance of *Helicobacter pylori* strains isolated from dyspeptic patients: a prevalence cross-sectional study in Spain. *Helicobacter.* 2017;22:e12440.
  49. Morilla AM, Alvarez-Arguelles ME, Duque JM, Armesto E, Vililar H, Melon S. Primary antimicrobial resistance rates and prevalence of *Helicobacter pylori* infection in the north of Spain. A 13-year retrospective study. *Gastroenterol Hepatol.* 2019;42:476–85.
  50. Cosme A, Torrente Iranzo S, Montes Ros M, Fernandez-Reyes Silvestre M, Alonso Galan H, Lizasoain J, et al. *Helicobacter pylori* antimicrobial resistance during a 5-year period (2013–2017) in northern Spain and its relationship with the eradication therapies. *Helicobacter.* 2019;24:e12557.
  51. Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, et al. Comparative effectiveness of multiple different first-line treatment regimens for *Helicobacter pylori* infection: a network meta-analysis. *Gastroenterology.* 2021;161:495–507.
  52. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther.* 2011;34:604–17.
  53. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Clin Exp Gastroenterol.* 2012;5:23–34.
  54. Gisbert JP, McNicholl AG. Eradication of *Helicobacter pylori* infection with non-bismuth quadruple concomitant therapy. In: Rahman AU, Choudhary MI, editors. *Frontiers in Anti-Infective Drug Discovery.* Bentham Science Publishers; 2020. p. 1–134.
  55. Espada M, Nyssen OP, Gisbert JP. Non-bismuth quadruple concomitant treatment for *H. pylori* eradication: systematic review and meta-analysis. *United Eur Gastroenterol J.* 2021, in press.
  56. Toros AB, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for *Helicobacter pylori* eradication in Turkey. *Helicobacter.* 2011;16:225–8.
  57. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, et al. Clinical outcomes of two-week sequential and concomitant therapies for *Helicobacter pylori* eradication: a randomized pilot study. *Helicobacter.* 2013;18:180–6.
  58. Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, et al. Concomitant and hybrid therapy for *Helicobacter pylori* infection: a randomized clinical trial. *J Gastroenterol Hepatol.* 2015;30:1361–6.
  59. Zhou L, Zhang J, Song Z, He L, Li Y, Qian J, et al. Tailored versus triple plus bismuth or concomitant therapy as initial *Helicobacter pylori* treatment: a randomized trial. *Helicobacter.* 2016;21:91–9.
  60. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Duenas-Sadornil C, Hernandez-Alonso M, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible *Helicobacter pylori* and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter.* 2012;17:269–76.
  61. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, et al. Optimized nonbismuth quadruple therapies cure most patients with *Helicobacter pylori* infection in populations with high rates of antibiotic resistance. *Gastroenterology.* 2013;145, 121–8, e121.
  62. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, et al. Randomised clinical trial comparing sequential and concomitant therapies for *Helicobacter pylori* eradication in routine clinical practice. *Gut.* 2014;63:244–9.
  63. Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, et al. Optimised empiric triple and concomitant therapy for *Helicobacter pylori* eradication in clinical practice: the OPTRICON study. *Aliment Pharmacol Ther.* 2015;41:581–9.
  64. McNicholl AG, Molina-Infante J, Bermejo F, Yarb H, Ferrer-Barcelo L, Modolell I, et al. Non bismuth quadruple “concomitant” therapies in the eradication of *Helicobacter pylori*: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice. *United Eur Gastroenterol J.* 2015;3:A65.

65. Cosme A, Lizasoan J, Montes M, Tamayo E, Alonso H, Mendarte U, et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of *Helicobacter pylori* in a region with high rate of clarithromycin resistance. *Helicobacter*. 2016;21:29–34.
66. McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Perez-Aisa A, Modolell I, et al. Probiotic supplementation with *Lactobacillus plantarum* and *Pediococcus acidilactici* for *Helicobacter pylori* therapy: a randomized, double-blind, placebo-controlled trial. *Helicobacter*. 2018;23:e12529.
67. Olmedo L, Azagra R, Aguye A, Pascual M, Calvet X, Gene E. High effectiveness of a 14-day concomitant therapy for *Helicobacter pylori* treatment in primary care. An observational multicenter study. *J Clin Med*. 2020;9.
68. Nyssen OP, Bordin D, Tepes B, Perez-Aisa A, Vaira D, Caldas M, et al. European Registry on *Helicobacter pylori* Management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. *Gut*. 2021;70:40–54.
69. Nyssen OP, Pérez-Aisa A, Vaira D, Jonaitis L, Tepes B, Keco-Huerga A, et al. First-line empirical *H. pylori* eradication therapy in Europe: results from 30,000 cases of the European Registry on *H. pylori* Management (Hp-EuReg). *United Eur Gastroenterol J*. 2021, in press.
70. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for *Helicobacter pylori* infection: systematic review and meta-analysis of sequential therapy. *BMJ*. 2013;347:f4587.
71. Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, et al. Meta-analysis: is sequential therapy superior to standard triple therapy for *Helicobacter pylori* infection in Asian adults? *J Gastroenterol Hepatol*. 2013;28:1801–9.
72. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential therapy or standard triple therapy for *Helicobacter pylori* infection: an updated systematic review. *Am J Ther*. 2015.
73. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of *Helicobacter pylori* in the community and hospital populations: a randomised trial. *Gut*. 2015.
74. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for *Helicobacter pylori* eradication. *Cochrane Database Syst Rev*. 2016;CD009034.
75. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for *Helicobacter pylori* eradication: a critical review. *J Clin Gastroenterol*. 2010;44:313–25.
76. Schwarzer A, Bontems P, Urruzuno P, Kalach N, Iwanczak B, Roma-Giannikou E, et al. Sequential therapy for *Helicobacter pylori* Infection in treatment-naïve children. *Helicobacter*. 2015;21:106–13.
77. Megraud F. The challenge of *Helicobacter pylori* resistance to antibiotics: the comeback of bismuth-based quadruple therapy. *Therap Adv Gastroenterol*. 2012;5:103–9.
78. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating *Helicobacter pylori* infection: a meta-analysis. *Aliment Pharmacol Ther*. 2003;17:1137–43.
79. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of *Helicobacter pylori* infection: systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol*. 2010;105:65–73.
80. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of *Helicobacter pylori* infection. *Digestion*. 2013;88:33–45.
81. Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. *Lancet*. 2016;388:2355–65.
82. Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuno J, et al. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for *Helicobacter pylori* infection: Spanish data of the European *Helicobacter pylori* Registry (Hp-EuReg). *Helicobacter*. 2020;25:e12722.
83. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al. *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet*. 2011;377:905–13.
84. Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of *Helicobacter pylori*. *Helicobacter*. 2019;24:e12570.
85. Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. *Gastroenterol Clin North Am*. 2015;44:537–63.
86. Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line *Helicobacter pylori* therapy. *Gut*. 2015;64:1715–20.
87. Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al. Adverse event profile during the treatment of *Helicobacter pylori*: a real-world experience of 22,000 patients from the European Registry on *H. pylori* management (Hp-EuReg). *Am J Gastroenterol*. 2021;116:1220–9.
88. Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, et al. European Registry on *Helicobacter pylori* Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice. *United Eur Gastroenterol J*. 2021;9:38–46.
89. Gomez Rodriguez BJ, Castro Laria L, Arguelles Arias F, Castro Marquez C, Caunedo Alvarez A, Romero Gomez M. A real life study of *Helicobacter pylori* eradication with bismuth quadruple therapy in naïve and previously treated patients. *Rev Esp Enferm Dig*. 2017;109:552–8.
90. Agudo-Fernandez S, Gonzalez Blanco A. Retrospective analysis of the use of quadruple therapy with bismuth (Pylera((R))) in real-life clinical practice in Spain. *Gastroenterol Hepatol*. 2018;41:483–9.
91. Perez-Arellano E, Rodriguez-Garcia MI, Galera Rodenas AB, de la Morena-Madrigal E. Eradication of *Helicobacter pylori* infection with a new bismuth-based quadruple therapy in clinical practice. *Gastroenterol Hepatol*. 2018;41:145–52.
92. Macias-Garcia F, Baston-Rey I, de la Iglesia-Garcia D, Calvino-Suarez C, Nieto-Garcia L, Dominguez-Munoz JE. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for *Helicobacter pylori* infection in an area of high resistance to clarithromycin: a prospective, cross-sectional, comparative, open trial. *Helicobacter*. 2019;24:e12546.
93. Castro Fernandez M, Romero Garcia T, Keco Huerga A, Pabon Jaen M, Lamas Rojas E, Llorca Fernandez R, et al. Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera(R)) to eradicate *Helicobacter pylori* infection in 200 patients. *Rev Esp Enferm Dig*. 2019;111:467–70.
94. Alcedo J, Gracia M, Garcia-Camara P, Palacin C, Gallego S, Jimeno-Ayllon C, et al. Prospective comparative study between two first-line regimens for *Helicobacter pylori* eradication: non-bismuth quadruple versus bismuth quadruple therapy. *Gastroenterol Hepatol*. 2020;43:301–9.
95. Nyssen OP, Perez-Aisa A, Keco-Huerga A, Castro-Fernández M, Lucendo A, Vaira D, et al. Experience with single capsule bismuth quadruple therapy in 5,000 patients from the European

- Registry on *H. pylori* Management (Hp-EuReg). United Eur Gas-troenterol J. 2021, in press.
96. Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line *Helicobacter pylori* eradication: a systematic review and meta-analysis. *Microb Pathog*. 2021;152:104661.
  97. McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, et al. Combination of bismuth and standard triple therapy eradicates *Helicobacter pylori* infection in more than 90% of patients. *Clin Gastroenterol Hepatol*. 2020;18:89–98.
  98. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for *Helicobacter pylori* eradication. *Helicobacter*. 1998;3:54–8.
  99. Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, et al. A new quadruple therapy for the eradication of *Helicobacter pylori*. Effect of pretreatment with omeprazole on the cure rate. *J Gastroenterol*. 1998;33:640–5.
  100. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for *Helicobacter pylori* eradication: a randomized controlled trial (MACLOR study). *Arch Intern Med*. 2002;162:153–60.
  101. Kwon BS, Park EB, Lee DH. Effectiveness of 5-day and 7-day quadruple “concomitant” therapy regimen for *Helicobacter pylori* infection in Korea. *Helicobacter*. 2011;16:135.
  102. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawad-wattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant *Helicobacter pylori* eradication therapy in Thailand. *Helicobacter*. 2012;17:282–5.
  103. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for *Helicobacter pylori* eradication: a prospective randomized study. *J Med Microbiol*. 2014;63:748–52.
  104. Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, et al. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: a real-life study. *Helicobacter*. 2020;25:e12694.
  105. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies. *Aliment Pharmacol Ther*. 2004;20:1071–82.
  106. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for *Helicobacter pylori* eradication: a randomized trial of 10 and 14 days. *Helicobacter*. 2011;16:295–300.
  107. Castells M, Khan DA, Phillips EJ. Penicillin allergy. *N Engl J Med*. 2019;381:2338–51.
  108. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther*. 2000;14:1319–28.
  109. Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. *Helicobacter pylori* first-line treatment and rescue options in patients allergic to penicillin. *Aliment Pharmacol Ther*. 2005;22:1041–6.
  110. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, Barrio J, Rodrigo L, Cosme A, et al. *Helicobacter pylori* first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. *Dig Liver Dis*. 2010;42:287–90.
  111. Gisbert JP, Maria Pajares J. [Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review]. *Med Clin (Barc)*. 2001;116:111–6.
  112. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, Aponte-Rivera E, Marxuach-Cuetara AM, Rodriguez-Orengo JF, et al. High eradication rates of *Helicobacter pylori* infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. *Dig Dis Sci*. 2005;50:634–9.
  113. Matsushima M, Suzuki T, Kurumada T, Watanabe S, Watanabe K, Kobayashi K, et al. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against *Helicobacter pylori* infection. *J Gastroenterol Hepatol*. 2006;21:232–6.
  114. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for *Helicobacter pylori*. *Aliment Pharmacol Ther*. 2007;26:343–57.
  115. Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernandez M, et al. *Helicobacter pylori* first-line and rescue treatments in the presence of penicillin allergy. *Dig Dis Sci*. 2015;60:458–64.
  116. Nyssen OP, Perez-Aisa A, Tapés B, Rodrigo-Saez L, Romero PM, Lucendo A, et al. *Helicobacter pylori* first-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on *H. pylori* management (Hp-EuReg). *Helicobacter*. 2020;25:e12686.
  117. Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant *Helicobacter pylori* infections in a prospective study. *Clin Gastroenterol Hepatol*. 2013;11, 802–7, e801.
  118. Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology*. 2020;159:697–705.
  119. Praitan MM, Iacono S, Francavilla R. Probiotics and *Helicobacter pylori* infection. *Med Univ*. 2012;14:217–23.
  120. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on *Helicobacter pylori* eradication: a systematic review and meta-analysis of randomized-controlled trials. *Eur J Gastroenterol Hepatol*. 2009;21:45–53.
  121. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of *Saccharomyces boulardii* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment. *Aliment Pharmacol Ther*. 2010;32:1069–79.
  122. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of *Lactobacillus*-containing and *Bifidobacterium*-containing probiotic compound preparation in *Helicobacter pylori* eradication therapy. *J Clin Gastroenterol*. 2013;47:25–32.
  123. Zheng X, Lyu L, Mei Z. *Lactobacillus*-containing probiotic supplementation increases *Helicobacter pylori* eradication rate: evidence from a meta-analysis. *Rev Esp Enferm Dig*. 2013;105:445–53.
  124. Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, et al. Meta-analysis of the efficacy of probiotics in *Helicobacter pylori* eradication therapy. *World J Gastroenterol*. 2014;20:18013–21.
  125. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on *Helicobacter pylori* eradication rates and side effects during eradication therapy: a meta-analysis. *PLoS One*. 2014;9:e111030.
  126. Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in *Helicobacter pylori* eradication therapy in children. *Eur J Pediatr*. 2014;173:153–61.

127. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in *Helicobacter pylori* eradication therapy: a systematic review and meta-analysis. *World J Gastroenterol.* 2015;21:4345–57.
128. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, et al. Efficacy and safety of probiotics as adjuvant agents for *Helicobacter pylori* infection: a meta-analysis. *Exp Ther Med.* 2015;9:707–16.
129. Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate *Helicobacter pylori*: a meta-analysis of randomized controlled trials. *Int J Clin Exp Med.* 2015;8:6530–43.
130. Lu C, Sang J, He H, Wan X, Lin Y, Li L, et al. Probiotic supplementation does not improve eradication rate of *Helicobacter pylori* infection compared to placebo based on standard therapy: a meta-analysis. *Sci Rep.* 2016;6:23522.
131. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for *Helicobacter pylori* eradication and prevention of adverse events. *United Eur Gastroenterol J.* 2016;4:546–61.
132. Lu M, Yu S, Deng J, Yan Q, Yang C, Xia G, et al. Efficacy of probiotic supplementation therapy for *Helicobacter pylori* eradication: a meta-analysis of randomized controlled trials. *PLoS One.* 2016;11:e0163743.
133. Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, et al. Probiotics in *Helicobacter pylori* eradication therapy: systematic review and network meta-analysis. *Clin Res Hepatol Gastroenterol.* 2017;41:466–75.
134. Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of *Helicobacter pylori* in children: a systematic review and network meta-analysis. *Eur J Clin Pharmacol.* 2017;73:1199–208.
135. Wen J, Peng P, Chen P, Zeng L, Pan Q, Wei W, et al. Probiotics in 14-day triple therapy for Asian pediatric patients with *Helicobacter pylori* infection: a network meta-analysis. *Oncotarget.* 2017;8:96409–18.
136. Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating *Helicobacter pylori*: a network meta-analysis. *Medicine (Baltimore).* 2019;98:e15180.
137. Dore MP, Bibbo S, Pes GM, Francavilla R, Graham DY. Role of probiotics in *Helicobacter pylori* eradication: lessons from a study of *Lactobacillus reuteri* strains DSM 17938 and ATCC PTA 6475 (Gastrus(R)) and a proton-pump inhibitor. *Can J Infect Dis Med Microbiol.* 2019;2019:3409820.
138. Efrati C, Nicolini G, Cannaviello C, O'Sed NP, Valabrega S. *Helicobacter pylori* eradication: sequential therapy and *Lactobacillus reuteri* supplementation. *World J Gastroenterol.* 2012;18:6250–4.
139. Manfredi M, Bizzarri B, de'Angelis GL. *Helicobacter pylori* infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. *Helicobacter.* 2012;17:246–53.
140. Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, et al. Association of a probiotic to a *Helicobacter pylori* eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. *BMC Gastroenterol.* 2013;13:56.
141. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for *Helicobacter pylori* infection: a randomized placebo-controlled triple-blind study. *Helicobacter.* 2013;18:280–4.
142. Hauser G, Salkic N, Vukelic K, JajacKnez A, Stimac D. Probiotics for standard triple *Helicobacter pylori* eradication: a randomized, double-blind, placebo-controlled trial. *Medicine (Baltimore).* 2015;94:e685.
143. Molina-Infante J, Gisbert JP. Probiotics for *Helicobacter pylori* eradication therapy: not ready for prime time. *Rev Esp Enferm Dig.* 2013;105:441–4.
144. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for *Helicobacter pylori* in the era of antibiotic resistance. *World J Gastroenterol.* 2014;20:10338–47.
145. Moreno Marquez C, Fernandez Alvarez P, Valdes Delgado T, Castro Laria L, Arguelles Arias F, Caunedo Alvarez A, et al. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic *Lactobacillus reuteri* in bismuth-containing quadruple eradication therapy for infection with *Helicobacter pylori*. *Rev Esp Enferm Dig.* 2021, <http://dx.doi.org/10.17235/reed.2021.7931/2021>. Online ahead of print.
146. Poonyam P, Chotivitayarakorn P, Vilaichone RK. High effective of 14-day high-dose PPI- bismuth-containing quadruple therapy with probiotics supplement for *Helicobacter pylori* eradication: a double blinded-randomized placebo-controlled study. *Asian Pac J Cancer Prev.* 2019;20:2859–64.
147. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for *Helicobacter pylori* eradication). *Expert Opin Pharmacother.* 2013;14:843–61.
148. Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, et al. Evidence-based guidelines for the treatment of *Helicobacter pylori* infection in Korea 2020. *Gut Liver.* 2021;15:168–95.
149. Nyssen OP, Pérez-Aisa A, Vaira D, Fiorini G, Rodrigo L, Keco-Huerga A, et al. Empirical second-line treatments in Europe: Results from the European Registry on *H. pylori* Management (Hp-EuReg). *United Eur Gastroenterol J.* 2021, in press.
150. Gisbert JP. Optimization strategies aimed to increase the efficacy of *Helicobacter pylori* eradication therapies with quinolones. *Molecules.* 2020;25:5084.
151. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after *Helicobacter pylori* treatment failure. *Aliment Pharmacol Ther.* 2006;23:35–44.
152. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent *Helicobacter pylori* infection: a meta-analysis. *Am J Gastroenterol.* 2006;101:488–96.
153. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent *Helicobacter pylori* infection: a meta analysis. *Wien Klin Wochenschr.* 2010;122:413–22.
154. Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for *Helicobacter pylori* eradication in second-line. *World J Gastroenterol.* 2012;18:5669–78.
155. Zhang M, Chen CY, Wang XT, Lyu B. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of *Helicobacter pylori* as the rescue therapy: a meta analysis]. *Zhonghua Nei Ke Za Zhi.* 2017;56:368–74.
156. Munoz N, Sanchez-Delgado J, Baylina M, Puig I, Lopez-Gongora S, Suarez D, et al. Systematic review, meta-analysis, and meta-regression: successful second-line treatment for *Helicobacter pylori*. *Helicobacter.* 2018;23:e12488.
157. Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, et al. Systematic review and network meta-analysis: comparative effectiveness of therapies for second-line *Helicobacter pylori* eradication. *J Gastroenterol Hepatol.* 2019;34:59–67.
158. Gisbert JP, Perez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, Barrio J, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate *Helicobacter pylori* infection: time trends in a Spanish Multicenter Study of 1000 patients. *J Clin Gastroenterol.* 2013;47:130–5.
159. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for *Helicobac-*

- ter pylori* eradication: systematic review and meta-analysis. *Drugs*. 2017;77:765–76.
160. Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of *Helicobacter pylori* in a high clarithromycin resistance area. *Helicobacter*. 2013;18:459–67.
  161. Gisbert JP, Molina-Infante J, Marin AC, Rodriguez GV, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate *H. pylori* infection. *Gastroenterology*. 2014;146 5 suppl.1. S-394.
  162. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for *Helicobacter pylori* re-treatment: role of bacterial resistance. *Dig Liver Dis*. 2007;39:1001–5.
  163. Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of *H. pylori* eradication with a sequential regimen followed by rescue therapy in clinical practice. *Dig Liver Dis*. 2010;42:541–3.
  164. Zullo A, Francesco V, Panella C, Morini S, Ierardi E. Second-line treatment for *Helicobacter pylori* eradication after sequential therapy failure: a pilot study. *Therapy*. 2006;3:251–4.
  165. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, et al. Concomitant, sequential, and hybrid therapy for *H. pylori* eradication: a pilot study. *Clin Res Hepatol Gastroenterol*. 2013;37:647–50.
  166. Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, et al. Second-line levofloxacin-based triple schemes for *Helicobacter pylori* eradication. *Dig Liver Dis*. 2009;41:480–5.
  167. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti- *Helicobacter pylori* therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a pilot study. *Helicobacter*. 2012;17:374–81.
  168. Malfertheiner P. Infection: bismuth improves PPI-based triple therapy for *H. pylori* eradication. *Nat Rev Gastroenterol Hepatol*. 2010;7:538–9.
  169. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. *Helicobacter*. 2013;18:373–7.
  170. Kahramanoglu Aksoy E, Pirincci Sapmaz F, Goktas Z, Uzman M, Nazligul Y. Comparison of *Helicobacter pylori* eradication rates of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen. *Med Princ Pract*. 2017;26:523–9.
  171. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for *Helicobacter pylori* treatment failures: a randomized clinical trial. *Scand J Gastroenterol*. 2015;50:1185–90.
  172. Bago P, Vcev A, Tomic M, Rozankovic M, Marusic M, Bago J. High eradication rate of *H. pylori* with moxifloxacin-based treatment: a randomized controlled trial. *Wien Klin Wochenschr*. 2007;119:372–8.
  173. Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, et al. Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for *Helicobacter pylori* infection. *Dig Dis Sci*. 2017;62:1580–9.
  174. Gan HY, Peng TL, Huang YM, Su KH, Zhao LL, Yao LY, et al. Efficacy of two different dosages of levofloxacin in curing *Helicobacter pylori* infection: a prospective, single-center, randomized clinical trial. *Sci Rep*. 2018;8:9045.
  175. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for *Helicobacter pylori* eradication. *World J Gastroenterol*. 2010;16:4357–62.
  176. Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo F, Molina-Infante J, et al. *Helicobacter pylori* second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. *Aliment Pharmacol Ther*. 2015;41:768–75.
  177. Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, et al. Quadruple rescue therapy for *Helicobacter pylori* infection after two treatment failures. *Eur J Clin Invest*. 2008;38:404–9.
  178. Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line *Helicobacter pylori* therapy after failure of non-bismuth quadruple therapy. *Dig Liver Dis*. 2016;48:506–11.
  179. Yee YK, Cheung TK, Chu KM, Chan CK, Fung J, Chan P, et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant *Helicobacter pylori* infection. *Aliment Pharmacol Ther*. 2007;26:1063–7.
  180. Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for *Helicobacter pylori* in Chinese patients: an open label, randomised, crossover trial. *Gut*. 2014;63:1410–5.
  181. Kim SJ, Baik GH, Kim JB, Kim JH, Kim YM, Kim DJ. Efficacy of the 14-day quadruple regimen (proton pump inhibitor, bismuth, tetracycline and metronidazole) as a rescue therapy after failure with the 10-days sequential therapy for eradication of *Helicobacter pylori*. *Gastroenterology*. 2010;138: S-470.
  182. Graham DY, Lu H. Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. *Aliment Pharmacol Ther*. 2015;41:1220–1.
  183. Cuadrado-Lavin A, Salcines-Cavedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, et al. Antimicrobial susceptibility of *Helicobacter pylori* to six antibiotics currently used in Spain. *J Antimicrob Chemother*. 2012;67:170–3.
  184. Fernandez-Reyes M, Tamayo E, Rojas-Rengifo D, Fischer W, Carrasco-Garcia E, Alonso M, et al. *Helicobacter pylori* pathogenicity and primary antimicrobial resistance in Northern Spain. *Eur J Clin Invest*. 2019;49:e13150.
  185. Ercin CN, Uygur A, Toros AB, Kantarcioglu M, Kilciler G, Polat Z, et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with *Helicobacter pylori* positive non-ulcer dyspepsia. *Turk J Gastroenterol*. 2010;21: 12–6.
  186. Telaku S, Manhxuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The efficacy of levofloxacin-based triple therapy for first-line *Helicobacter pylori* eradication. *Med Arch*. 2013;67:348–50.
  187. Tai WC, Chuah SK, Wu KL. The efficacy of second-line anti-*Helicobacter pylori* eradication using 10-day and 14-day levofloxacin-containing triple therapy. *United Eur Gastroenterol J*. 2013;1(1S):A5.
  188. Cheng HC, Chang WL, Chen WY, Yang HB, Wu JJ, Sheu BS. Levofloxacin-containing triple therapy to eradicate the persistent *H. pylori* after a failed conventional triple therapy. *Helicobacter*. 2007;12:359–63.
  189. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for *Helicobacter pylori* Infection. *Gastroenterol Clin North Am*. 2010;39:465–80.
  190. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C. Second-line and rescue therapies for *Helicobacter pylori* eradication in clinical practice. *J Gastrointestin Liver Dis*. 2010;19:131–4.

191. McNicholl AG, Gisbert JP. Warnings on the safety of quinolones: should *Helicobacter pylori* treatment prescriptions be modified? *Gastroenterol Hepatol.* 2019;42:461–3.
192. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults. *Gastroenterology.* 2016;151, 51–69, e14.
193. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of *Helicobacter pylori* eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. *Helicobacter.* 2017;22.
194. Furuta T, Sugimoto M, Yamada M, Uotani T, Sahara S, Ichikawa H, et al. Eradication of *H. pylori* infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. *Intern Med.* 2014;53:571–5.
195. Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and *gyrA* mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for *Helicobacter pylori* in penicillin allergic patients. *United Eur Gastroenterol J.* 2017;5:796–804.
196. Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for *H. pylori* infection. *Dig Dis Sci.* 2014;59:383–9.
197. Rodriguez de Santiago E, Martin de Argila de Prados C, Marcos Prieto HM, Jorge Turrian MA, Barreiro Alonso E, Flores de Miguel A, et al. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera((R))) in third-line rescue treatment for *Helicobacter pylori* infection. A real-life multi-center study. *Helicobacter.* 2017;22:e12423.
198. Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored therapy versus empiric chosen treatment for *Helicobacter pylori* eradication: a meta-analysis. *Medicine (Baltimore).* 2016;95:e2750.
199. Gisbert JP, Pajares JM. *Helicobacter pylori* “rescue” therapy after failure of two eradication treatments. *Helicobacter.* 2005;10:363–72.
200. Gisbert JP, Castro-Fernandez M, Bermejo F, Perez-Aisa A, Ducons J, Fernandez-Bermejo M, et al. Third-line rescue therapy with levofloxacin after two *H. pylori* treatment failures. *Am J Gastroenterol.* 2006;101:243–7.
201. Gisbert JP. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2012;35:1484–5, author reply 1486.
202. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. *Aliment Pharmacol Ther.* 2005;22:45–9.
203. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two *Helicobacter pylori* treatment failures. *Aliment Pharmacol Ther.* 2006;24: 1469–74.
204. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative *H. pylori* eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. *Am J Gastroenterol.* 2009;104:21–5.
205. Burgos-Santamaria D, McNicholl AG, Gisbert JP. Empirical *Helicobacter pylori* rescue therapy: an 18-year singlecentre study of 1200 patients. *GastroHep.* 2019;1:311–24.
206. Burgos-Santamaria D, Nyssen OP, Vaira D, Niv Y, Tepes B, Fiorini G, et al. European Registry on *H. pylori* Management (Hp-EuReg): analysis of 1,782 empirical rescue therapies on third and subsequent lines. *United Eur Gastroenterol J.* 2020;8:85.
207. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2012;35:209–21.
208. Gisbert JP. Rifabutin for the treatment of *Helicobacter pylori* infection: a review. *Pathogens.* 2020;10:15.
209. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after *Helicobacter pylori* treatment failure: a 10-year single-centre study of 500 patients. *Aliment Pharmacol Ther.* 2008;27:346–54.
210. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of *Helicobacter pylori* eradication treatment: preliminary experience. *J Clin Gastroenterol.* 2000;31:222–5.
211. Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent *Helicobacter pylori* resistant to both metronidazole and clarithromycin. *Helicobacter.* 2008;13:69–74.
212. van Zanten SV, Desai S, Best L, Cooper-Lesins G, Malatjalian D, Haldane D, et al. Rescue therapy using a rifabutin-based regimen is effective for cure of *Helicobacter pylori* infection. *Can J Gastroenterol.* 2010;24:303–6.
213. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, et al. Fourth-line rescue therapy with rifabutin in patients with three *Helicobacter pylori* eradication failures. *Aliment Pharmacol Ther.* 2012;35:941–7.
214. Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, et al. Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for *Helicobacter pylori* infection. *Eur J Intern Med.* 2020;81:50–3.
215. Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory *Helicobacter pylori* infection: a prospective single-arm study. *Helicobacter.* 2020;25:e12719.
216. Nyssen OP, Vaira D, Fiorini G, Saracino IM, Caldas M, Boltin D, et al. Experience with rifabutin-containing therapy in 426 patients from the European Registry on *H. pylori* Management (Hp-EuReg). *United Eur Gastroenterol J.* 2021, in press.
217. Ierardi E, Giangaspero A, Losurdo G, Giorgio F, Amoruso A, De Francesco V, et al. Quadruple rescue therapy after first and second line failure for *Helicobacter pylori* treatment: comparison between two tetracycline-based regimens. *J Gastrointest Liver Dis.* 2014;23:367–70.
218. Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, et al. *Helicobacter pylori* eradication in Western Australia using novel quadruple therapy combinations. *Aliment Pharmacol Ther.* 2012;36:1076–83.
219. Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of *Helicobacter pylori* infection: two pilot studies. *Helicobacter.* 2016;21:375–81.
220. Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, et al. High dose PPI-amoxicillin dual therapy for *Helicobacter pylori* infection: a systematic review with meta-analysis. *Therap Adv Gastroenterol.* 2020;13:1756284820937115.
221. Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for *Helicobacter pylori* infection: an update based on a systematic review and meta-analysis. *Helicobacter.* 2020;25:e12692.
222. Gisbert JP, Boixeda D, Martin de Argila C, Garcia Plaza A. [*Helicobacter pylori* and duodenal ulcer: a causal relation or mere association?]. *Rev Clin Esp.* 1997;197:693–702.
223. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? *Aliment Pharmacol Ther.* 2005;21:795–804.

224. Colin R. Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. *Aliment Pharmacol Ther.* 2002;16:1157–62.
225. Hsu CC, Lu SN, Changchien CS. One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on *Helicobacter pylori* eradication and ulcer healing. *Hepatogastroenterology.* 2003;50:1731–4.
226. Labenz J, Idstrom JP, Tillenburg B, Peitz U, Adamek RJ, Borsch G. One-week low-dose triple therapy for *Helicobacter pylori* is sufficient for relief from symptoms and healing of duodenal ulcers. *Aliment Pharmacol Ther.* 1997;11:89–93.
227. Marzio L, Cellini L, Angelucci D. Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with *Helicobacter pylori* infection. A double blind placebo controlled trial. *Dig Liver Dis.* 2003;35:20–3.
228. Tepes B, Krizman I, Gorensen M, Gubina M, Orel I. Is a one-week course of triple anti-*Helicobacter pylori* therapy sufficient to control active duodenal ulcer? *Aliment Pharmacol Ther.* 2001;15:1037–45.
229. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, Rudzinski J, Bartuzi Z, et al. One week of treatment with esomeprazole-based triple therapy eradicates *Helicobacter pylori* and heals patients with duodenal ulcer disease. *Eur J Gastroenterol Hepatol.* 2001;13:1457–65.
230. Subei IM, Cardona HJ, Bachelet E, Useche E, Arribabu A, Hammour AA, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in *Helicobacter pylori*-positive patients. *Dig Dis Sci.* 2007;52:1505–12.
231. Takeuchi T, Umegaki E, Takeuchi N, Yoda Y, Kojima Y, Tokioka S, et al. Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple *Helicobacter pylori* eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers. *J Clin Biochem Nutr.* 2012;51:189–95.
232. Treiber G, Lambert JR. The impact of *Helicobacter pylori* eradication on peptic ulcer healing. *Am J Gastroenterol.* 1998;93:1080–4.
233. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer. *Aliment Pharmacol Ther.* 2001;15:1949–58.
234. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of *Helicobacter pylori* in patients with gastric ulcer but not duodenal ulcer haemorrhage. *Aliment Pharmacol Ther.* 2000;14:1071–6.
235. Higuchi K, Fujiwara Y, Tominaga K, Watanabe T, Shiba M, Nakamura S, et al. Is eradication sufficient to heal gastric ulcers in patients infected with *Helicobacter pylori*? A randomized, controlled, prospective study. *Aliment Pharmacol Ther.* 2003;17:111–7.
236. Tulassay Z, Stolte M, Sjolund M, Engstrand L, Butruk E, Malfertheiner P, et al. Effect of esomeprazole triple therapy on eradication rates of *Helicobacter pylori*, gastric ulcer healing and prevention of relapse in gastric ulcer patients. *Eur J Gastroenterol Hepatol.* 2008;20:526–36.
237. Gisbert JP, Pajares JM. *Helicobacter pylori* and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication? *Scand J Gastroenterol.* 2003;38:2–9.
238. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. *H. pylori* eradication therapy vs. anti-secretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. *Cochrane Database Syst Rev.* 2004;CD004062.
239. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: *Helicobacter pylori* eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. *Aliment Pharmacol Ther.* 2004;19:617–29.
240. Amendola M, Farias R, Katz J, Luna P, Ianella M, Musi A, et al. [Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of *Helicobacter pylori*]. *Acta Gastroenterol Latinoam.* 1999;29:47–50.
241. Arkkila PE, Seppala K, Kosunen TU, Haapiainen R, Kivilaakso E, Sipponen P, et al. Eradication of *Helicobacter pylori* improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer. *Am J Gastroenterol.* 2003;98:2149–56.
242. Capurso G, Annibale B, Osborn J, D'Ambra G, Martino G, Lahner E, et al. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2001;15:821–9.
243. Gisbert JP, Boixeda D, Aller R, de la Serna C, Sanz E, Martin de Argila C, et al. [*Helicobacter pylori* and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]. *Med Clin (Barc).* 1999;112:161–5.
244. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of *Helicobacter pylori* reduces the rate of rebleeding in peptic ulcer disease. *Scand J Gastroenterol.* 1993;28:939–42.
245. Horvat D, Vcev A, Soldo I, Timarac J, Dmitrovic B, Misevic T, et al. The results of *Helicobacter pylori* eradication on repeated bleeding in patients with stomach ulcer. *Coll Antropol.* 2005;29:139–42.
246. Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. *Helicobacter pylori* eradication reduces the rate of rebleeding in ulcer hemorrhage. *Gastrointest Endosc.* 1995;41:5–7.
247. Jaspersen D, Korner T, Schorr W, Brennenstuhl M, Hammar CH. Omeprazole-amoxicillin therapy for eradication of *Helicobacter pylori* in duodenal ulcer bleeding: preliminary results of a pilot study. *J Gastroenterol.* 1995;30:319–21.
248. Krizman I, Ribnikar M, Kozek F, Primozic S. Comparative amoxicillin Azithromycin treatment of *Helicobacter pylori* positive patients with bleeding duodenal ulcer. *Acta Pharmaceutica.* 1997;47:183–8.
249. Labenz J, Borsch G. Role of *Helicobacter pylori* eradication in the prevention of peptic ulcer bleeding relapse. *Digestion.* 1994;55:19–23.
250. Lai KC, Hui WM, Wong WM, Wong BC, Hu WH, Ching CK, et al. Treatment of *Helicobacter pylori* in patients with duodenal ulcer hemorrhage—a long-term randomized, controlled study. *Am J Gastroenterol.* 2000;95:2225–32.
251. Liu CC, Lee CL, Chan CC, Tu TC, Liao CC, Wu CH, et al. Maintenance treatment is not necessary after *Helicobacter pylori* eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. *Arch Intern Med.* 2003;163:2020–4.
252. Macri G, Milani S, Surrenti E, Passaleva MT, Salvadori G, Surrenti C. Eradication of *Helicobacter pylori* reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. *Am J Gastroenterol.* 1998;93:925–7.
253. Pellicano R, Peyre S, Leone N, Repici A, De Angelis C, Rizzi R, et al. The effect of the eradication of *Helicobacter pylori* infection on hemorrhage because of duodenal ulcer. *J Clin Gastroenterol.* 2001;32:222–4.
254. Riemann JF, Schilling D, Schauwecker P, Wehlen G, Dorlars D, Kohler B, et al. Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in *Helicobacter pylori*-associated peptic ulcer bleeding. *Gastrointest Endosc.* 1997;46:299–304.

255. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of *Helicobacter pylori* reduces the possibility of rebleeding in peptic ulcer disease. *Gastrointest Endosc.* 1995;41:1–4.
256. Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for *Helicobacter pylori* infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. *Am J Gastroenterol.* 1996;91:1549–52.
257. Sung JJ, Leung WK, Suen R, Leung VK, Chan FK, Ling TK, et al. One-week antibiotics versus maintenance acid suppression therapy for *Helicobacter pylori*-associated peptic ulcer bleeding. *Dig Dis Sci.* 1997;42:2524–8.
258. Vcev A, Horvat D, Rubinic M, Stimac D, Vceva A, Uravic M, et al. Eradication of *Helicobacter pylori* reduces the possibility of rebleeding in duodenal ulcer disease. *Acta Fam Med Flum.* 1996;21:59–65.
259. Vergara M, Casellas F, Saperas E, de Torres I, Lopez J, Borruel N, et al. *Helicobacter pylori* eradication prevents recurrence from peptic ulcer haemorrhage. *Eur J Gastroenterol Hepatol.* 2000;12:733–7.
260. Gisbert JP, Calvet X, Cosme A, Almela P, Feu F, Bory F, et al. Long-term follow-up of 1,000 patients cured of *Helicobacter pylori* infection following an episode of peptic ulcer bleeding. *Am J Gastroenterol.* 2012;107:1197–204.
261. Chang SS, Hu HY. *Helicobacter pylori* eradication within 120 days is associated with decreased complicated recurrent peptic ulcers in peptic ulcer bleeding patients. *Gut Liver.* 2015;9:346–52.
262. Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, et al. Optimal initiation of *Helicobacter pylori* eradication in patients with peptic ulcer bleeding. *World J Gastroenterol.* 2015;21:2497–503.
263. Guo CG, Cheung KS, Zhang F, Chan EW, Chen L, Wong ICK, et al. Delay in retreatment of *Helicobacter pylori* infection increases risk of upper gastrointestinal bleeding. *Clin Gastroenterol Hepatol.* 2021;19, 314–22, e312.
264. Pérez-Aisa A, Nyssen OP, Lucendo A, Barrio J, Gomez BJ, Di Maira T, et al. Terapia erradicadora cuádruple con bismuto en cápsula única (Pylera®): ¿3 ó 4 veces al día? Subanálisis de los datos españoles del Registro Europeo de *H. pylori* (Hp-EuReg). *Gastroenterol Hepatol.* 2021;44:143.